INDEX TO VOLUME 182

Author Index

Abadi, G. K., 564
Abel, L., 405
Aberer, E., 1455
Abraham, B., 1005
Abrams, E. J., 104
Abu-Elyazeed, R., 685
Acosta, E., 1375
Adam, D., 509
Adam, D. E., 1097
Adams, G. J., 1425
Adams, G. L., 882
Adelsberger, J., 1063
Adult/Adolescent Spectrum of HIV Disease Project, 611
Agosti, J. M., 1531
Aguilar, M., 1199
AIDS Clinical Trials Group 209 and 214 Study Teams, 1357
AIDS Clinical Trials Group Protocol 333 Team, 733
AIDS Clinical Trials Group Study 359 Protocol Team, 1375
Akagawa, H., 1276
Akhtar, S., 1260
Akhyani, N., 1321
Akre, T., 678
Akuffo, H., 570
Alagaratnam, M., 168
Albini, A., 1643
Alcabes, P., 359
Alcantara, A. P., 1531
Allan, B., 1239, 1578
Allignet, J., 351
Almela, M., 833, 840
Altwegg, M., 1540
Amin, A., 517
Amini, S., 1247
Ammassari, A., 1077
Anastos, K., 1084, 1527
Anderson, D. C., 1051
Anderson, E. L., 1331
Anderson, M., S54
Andersson, G., 1756
Andersson, J., 1625
Andréoletti, L., 1222
Andreoni, M., 1574
Angus, B., 629
Antinori, A., 1077
Anton, P., 1625
Anzala, A. O., 459
Arala-Chaves, M., 266
Aratani, Y., 1276
Araujo, F. G., 356
Archibald, L. K., 474
Areschoug, T., 142
Armstrong, W., 551
Arnold, R. L., 1304, 1311
Arntzen, C. J., 302
Arribas, A., 955
Arthur, R. R., 698
Asadulghani, M. N., 1161
Ashgar, H., 6
Ashur, Y., 1005
Aspelin, T., 133
Assis, A. M. O., 1800
Astley, S. B., S11
Atherton, J. C., 1450
Atkinson, B., 420
Auer, M., 347
Aufwerber, E., 840
Augustine, N. H., 974
Ausiello, C. M., 1575
Avendaño, L. F., 1519
Ayisi, J., 960
Aymard, G., 112
Aymard, M., 290
Azuma, M., 180
Baarsma, G. S., 923
Bacher, J. S., 274
Badaro, R., 1531
Baghian, A., 928
Bahia, F., 1531
Bahia-Oliveira, L. M. G., 634
Bailey, A. L., S11
Bailey, R. L., 1545
Baker, C. J., 413, 1129, 1385
Baker, S. C., 1183
Bale, J. F., Jr., 933
Ball, T. B., 459
Ballow, A., 1616
Balter, S., 1553
Baqi, M., 123
Barbero, A., 1643
Barnes, P. F., 234
Barr, M. C., 725
Barreto, M. L., 1800
Barroga, C. F., 413
Barth Reller, L., 1251
Basco, L. K., 624
Baseler, M., 1063
Baskin, G. B., 708
Bassett, R., 733
Baughman, W., 1417
Baughn, R. E., 158
Baum, M. K., S69
Bayer, A. S., 1251
Bayerlein, I., 1437
Beall, B., 1109
Beall, D. S., 1169
Beard, C. B., 1192
Beauchamp, D., 1255
Beck, M. A., S93
Bélec, L., 112, 1090
Bell, D., 1357
Bell, M., 474
Belshe, R. B., 1331
Benelli, R., 1643
Benjamim, C. F., 214
Benoist, H., 1394
Bergamini, A., 776
Bergeron, M. G., 970, 1255
Bergeron, Y., 1255
Bernard, M.-C., 112
Bernstein, D. I., 1304
Berrey, M. M., 950
Berrios, L., 316
Berti, R., 1321
Bessen, D. E., 1109
Bharadwaj, M., 43
Biasin, M., 1365
Bienzle, D., 123
Biggar, R. J., 1574
Biggerstaff, B. J., 616
Bijlsma, J. J. E., 1566
Bilger, K., 290
Billaud, J.-N., 725
Binley, J. M., 945
Birch, C. J., 941
Bisgard, K. M., 1402
Bistoni, F., 824
Bittoova, M., 643
Black, F., 1574
Blaner, W. S., S97
Blankson, J. N., 1636
Blanton, R. E., 1800
Blaser, M. J., 1446, 1578
Blatter, M. M., 1005
Blé, C., 1365
Bloch, L. M., 856
Blomberg, J., 49
Bluethmann, H., 180
Bode, G., 1446
Bodison, S., 1486
Boivin, G., 378
Bolacchi, F., 776
Bongiovanni, B., 776
Bonville, C. A., 1022
Boom, W. H., 1658
Borchers, A. T., S108
Borgdorff, M. W., 1788
Borkowsky, W., 88, 96, 1616
Borrow, R., 1557
Boschi-Pinto, C., 379
Boucher, C. A. B., 59, 733
Boulianne, N., 174
Bourlet, T., 1222
Bowden, D. S., 941
Bower, W. A., 12
Boyce, T. G., 1331
Bøyum, A., 1784
Braconier, J. H., 1005
Brambilla, A., 311, 1579
Brandtzaeg, P., 1784
Brassard, J., 334
Braun, J. S., 150
Braun, P. A., 1694
Brennan, M. B., 1321
Brenner, H., 1446
Breschkin, A. M., 941
Briese, T., 1214
Briles, D. E., 1146, 1694
Brites, C., 1531
Brito-Avô, A., 1153
Brockhaus, M., 978
Broder, C. C., 68
Brodeur, B. R., 848
Brojanac, S., 1610
Bröker, B. M., 367
Brown, D. W. G., 1090
Brown, K. A., 1039
Brugghe, H. F., 923, 1672
Brunner, M., 534
Bryan, R. T., 1503
Bryant, A. E., 799, 808, 1117
Bryson, Y. J., 751
Buchanan, I., 474
Buchanan, W., 79
Bukh, J., 698
Bukusi, E. A., 1672
Bulach, D. M., 941
Bulkow, L. R., 490
Bull, P. C., 252
Bulterys, M., 104
Buonocore, L., 1228
Burchett, S. K., 1385, 1616
Burckhardt, B., 950
Burkot, T. R., 616
Burman, W., 551
Burroughs, A. K., 1610
Bussolino, F., 1643
Butler, J. C., 490
Buurman, W. A., 564
Bwayo, J. J., 459, 1672
Cabral, S., 1769
Cabrera, L., 865
Califano, C., S115
Calva, J. J., 1602
Calvo-Calle, J. M., 1486
Camoglio, L., 902
Camp, N. J., 1557
Campa, A., S69
Campo, M. L., 359
Campos-Neto, A., 224
Cançado, J. R., 634
Candelario, M., 274
Cao, H., 1350
Capobianchi, A., 376
Capozzi, M., 776
Capparelli, E. V., 1616
Cappelli, G., 776
Capra, W. B., 428
Capucci, S., 376

Caputo, S. L., 1365
Carapetis, J. R., 1109
Carella, A., 698
Carey, V. J., 1129
Carithers, R. L., Jr., 397
Carlone, G. M., 1146
Carrol, E. D., 363
Carter, J. T., 941
Carter, J. L., 1192
Casadevall, A., 1791
Casey, R., 1331
Caspar-Bauguil, S., 1394
Cassatella, M., 1643
Casseb, J., 379
Cassiday, P., 1402
Cassone, A., 1575
Castaño, G. C., 294
Castro, Z. R., 1486
Cate, T. R., 1425
Catton, M. G., 941
Cavrois, M., 1044
Cellesi, C., 1577
Cepparulo, M., 776
Cessot, G., 112
Chadwick, K., 1636
Chai, F., S85
Chaicumpa, W., 371
Chan, I., 1005
Chandwani, R., 88
Chang, A., 1218
Chang, S.-Y., 442
Chang, Y., 306
Chanock, R. M., 1331
Chao, C. C., 200
Chaowagul, W., 206
Chapkin, R. S., S103
Chapman, B., 607
Chapman, S. W., 1280
Charoenpanich, P., 1652
Chaudhary, A. G. A., 1557
Chazin, W. J., 1272
Chen, L. B., 607
Chen, M. D., 1228
Chen, R. Y. Z., 799, 808
Chen, X. Q., 1005
Chen, Y., 79
Chêne, G., 36, 599
Cheng, H., 1375
Chernoff, D., 1357
Chervenak, K., 1658
Chibo, D., 941
Chico, M. E., 1199, 1207
Chien, C.-C., 620
Chiu, S., 1357
Chiulli, M., 316
Chmura, K., 1001
Choo, S., 1260
Chotivanich, K., 629
Chou, S., 1765
Chuangsuwanich, T., 1652
Church, J., 1774
Cianferoni, L., 1365
Cinatl, J., 643
Cinatl, J., Jr., 643
Cinco, M., 1455
Cingolani, A., 1077
Clas, B., 945
Cleary, J. D., 1280
Clemens, J. D., 685
Clemente, G., 526
Clements, D., 1005
Clerici, M., 639, 1365, 1811
Clot, J., 1285
Clumeck, N., 950
Cochrane, A., 1515
Cohen, A. M., 1722
Cohen, C. R., 1672
Cohen, M. H., 1084, 1527
Cohen, P., 376
Colantuoni, V., S97
Cole, R., 1425
Coler, R. N., 224
Colizzi, V., 776
Collier, A. C., 603, 733, 1357
Collingridge, T., 1109
Collins, R. D., 671
Colombo, F., 1365
Condra, J. H., 733, 758
Connick, E., 1070
Contos, M. J., 1595
Conway, D. J., 1545
Coombs, R. W., 733
Cooney, E., 1357
Cooper, D. A., 334, 428, 950
Cooper, E., 1243
Cooper, P. J., 1199, 1207
Cope, A. V., 1610
Corbeau, P., 1285
Corey, G. R., 1251
Corey, L., 662, 950
Correa-Oliveira, R., 634
Corsaro, D., 1577
Cortese, J. F., 993
Costa, C. H. N., 997
Costello, R., 1583
Cosyns, M., 1001
Cotler, S., 397
Cotte, L., 381
Couillard, M., 691
Courssaris, B., 123
Cousins, R. J., S81
Couture, F., 848
Couzi, L., 36
Cowles, M. K., 1385
Cox, N. J., 1218
Craig, C., 733
Crane, L., 551
Crawford, S. E., 1183
Creasman, J., 1192
Crowe, J. E., Jr., 1331
Crumpacker, C. S., 607
Csako, G., 1583
Cuenca, S., 1268
Culnane, M., 1616
Cunha, F. Q., 214
Cunningham-Rundles, S., S115
Currie, B. J., 1109
Curtin, P. T., 428
Curtis, S. J., 1326
Cusi, M. G., 1577
Cusini, M., 311
Dagan, R., 1005
D'Agostino, C., 1536
Dahari, H., 28
Dahl, T. A., 607
Dankner, W. M., 1616
Das, B. S., S23
Daugherty, S., 970
Davey, R. T., Jr., 1063
Davey, V., 435
David, J. R., 997
Davidian, M., 28
Davidson, F., S134
Dawson, J., 933
Dean, D., 909
DeBruin, M., 1070
Decazes, J.-M., 599
DeCicco, K. L., S29
de Coul, K. O., 1291
DeGruttola, V., 59, 1357
de Haas, P. E. W., 1788
Dehesa, M., 1450
DeHovitz, J. A., 1527
de Jonge, E., 1264
Dekkers, P. E. P., 888
de Lencastre, H., 1153
Delgado, J., 865
del Rio, C., 1192
De Luca, A., 1077
de Magalhaes Queiroz, D. M., 1008
Demeter, L. M., 316
Demmler, G. J., 933
Dentener, M. A., 564
deRosayro, J., 1051
Déry, P., 174
De Serres, G., 174
de Sorrentino, A. H., 1523
De Sousa, M., S115
Detels, R., 1247
de Thé, G., 405
d'Ettorre, G., 1536
DeVille, J., 751, 1774
Dewar, R. L., 1063
Dexter, A., 316
Dezube, B. J., 607
d'Halewyn, M.-A., 691
DiAngelo, S., 1473
Dietrich, M., 367
Diggs, C., 1486
di Giovine, F. S., 1557
Dinarello, C. A., 1722
Ding, M., 79
Dings, M. E. M., 923
Diourte, Y., 993
Diquet, B., 112
Djimde, A., 993
Dobbie, H., 474
Dobroszycki, J., 88
Doerr, H. W., 643
Dolan, M. C., 616
Domachowske, J. B., 1022
Domagala, J., 517
Dondorp, A., 629
Dong, L., 391
Dong, Y., 517
Douglas, S. D., 96
Doumbo, O. K., 993
Douville Fradet, M., 174
Doyle, T. J., 1503
Drew, W. L., 1765
Drlica, K., 517
Drohan, L. A., 766
Duchin, J. S., 1192
Duff, G. W., 1557
Dunn, J. J., 298
Durrer, P., 1540
Duval, B., 174
Dworkin, M. S., 611
Dwyer, R., 840
Dykes, C., 316
Eaton, J. M., 1321
Eckert, L. O., 540
Edelman, R., 1486
Edwards, C. K., III, 1722
Edwards, K. M., 1425
Eichelberger, M., 1331
Eichler, H.-G., 343
Eick, A., 474
Eisen, G., 467
Ekouevi, D., 36
Elashoff, M., 435
Elitsur, Y., 1007
Elliott, J., 1625
Ellis, D., 1013
Ellner, J., 1350
El Solh, N., 351
Emery, S., 428
Emery, V. C., 1610
Emini, E. A., 758
Endtz, H., 816
English, B. K., 1561
Englund, J. A., 413, 1385
Epstein, S. E., 1583
Equils, O., 751
Erickson, K. L., S5
Eskola, J., 1425
Espinel, I., 1199, 1207
Essex, M., 442, 1531
Estes, M. K., 302
Evans-Strickfaden, T., 1051
Evdokiou, A., S85
Eyster, M. E., 590
Ezzell, R. M., 873, 1578
Fahle, G. A., 1006
Falloon, J., 1063
Fangon, M. C., 413
Farhat, S., 595
Farley, M. M., 1417
Faruque, S. M., 1161
Fauci, A. S., 1804
Fawzi, W. W., S122

Feinberg, M. B., 435
Feiveson, A. H., 1761
Feldman, J. G., 1527
Feldmesser, M., 1791
Feng, C., S54
Fennelly, G., 88
Fenton, T., 1769, 1774
Fenyö, E.-M., 49
Ferbas, J., 1247
Ferchal, F., 599
Ferguson, L. M., 1694
Feris, J., 1553
Fernandez, J., 1553
Ferrante, P., 1365
Ferrari, T. C., 634
Ferreira, P., 266
Ferreira, S. H., 214
Ferrini, S., 1643
Fichtenbaum, C., 955
Fidel, P. L., Jr., 955, 1479
Fierman, A., 359
Fierz, W., 1810
Fife, K. H., 321
Filié, Y., 260
Finegold, S., 799, 808
Finglas, P. M., S11
Finn, A., 1260
Finn, L. S., 1183
Finzi, D., 1636
Fischer, D., 1268
Fischer, J. E., 1029, 1288
Fischer, N., 1214
Fischer, S. H., 1006
Fischetti, V. A., 1712
Fischl, M., 1375
Fiscus, S. A., 1375
FitzGerald, G., 1243
Fiuza, C., 526
Flanigan, T. P., 603
Fleisch, F., 1540
Fleischer, B., 367
Fletcher, C. V., 326, 1375, 1769, 1774
Fleury, H., 36
Floros, J., 1473
Florquin, S., 902
Fogelman, I., 435
Fontán, P. A., 1712
Fontana, A., 978
Forcina, G., 1536
Fotheringham, N., 970
Foulkes, A. S., 59
Fowler, V. G., Jr., 1251
Fox, A. J., 1557
Fox, J. G., 620
Fox, L., 321
Fraker, P. J., S16
Franzetti, F., 639
Fredriksson, R., 49
Frei, K., 978
Freimuth, W., 1375
French, A. L., 1084
Frenck, R. W., 685
Frendéus, B., 1738
Frenkel, L. M., 1616
Frey, S., 1005
Frider, B., 294
Friedland, G. H., 321, 1357
Fries, A., 49
Frishman, J. I., 1722
Fritsche, K. L., S54
Fuchs, D., 716
Fujihashi, K., 180
Furukawa, Y., 1343
Fusi, M. L., 639
Fyfe, G. A., 428
Gaggero, A., 1519
Galdbart, J.-O., 351
Gallagher, B., 766
Galliani, C. A., 1183
Gamble, M. V., S97
Gange, S. J., 1527
Gao, Y.-T., 1300
Gaora, P. Ó., 895
Garcez, L. M., 997
García, A., 1473
García, L. F., 240
Gares, M.-P., 895
Garratty, E., 751
Garrigue, I., 36
Garrison, K. M., 1409
Gascón, J., 1780
Gastaldi, R., 376
Gay, K., 1417
Gaye-Diallo, A., 467
Gazzard, B., 792
Gazzinelli, G., 634
Ge, Y., 873
Gentile, G., 376
Gentile, M., 1077
Georgievska, L., 49
Gern, L., 1455
Gershwin, M. E., S108
Gerstoft, J., 744
Gervassi, L., 224
Gessain, A., 405, 1044
Ghezzi, S., 311, 1579
Giancola, M. L., 1077
Giardina, P. J., S115
Giesick, J. S., 1218
Gilbert, M. J., 1531
Gill, J., 792
Gillies, S. D., 607
Gilman, R. H., 865
Ginsberg, M. M., 1218
Giorgi, J. V., 1247, 1625
Girard, W. M., 234
Giri, N., 274
Girmenia, C., 376
Glass, R. I., 685, 1602
Glaumann, H., 1756
Glidden, D. V., 733
Goade, D., 43
Godaly, G., 1738
Goedert, J. J., 590
Goldberg, J. D., 1284
Goldsmith, J., 1616
Goldstein, M., 856
Gomes, J. A. S., 634
Gomes, R. B. B., 997
Gonin, P., 691
González-Valencia, G., 1450
Goodman, J. L., 200
Gopal, R., 1090
Gopinath, R., 1804
Gori, A., 639
Gosselin, B., 1222
Gotch, F. M., 792
Gottesman, M. E., S97
Götz, F., 1688
Goujon, C., 112
Gout, O., 1044
Govindarajan, S., 1300
Grady, R. W., S115
Grafakos, S., 965
Graham, B., 1774
Graham, B. S., 671, 1029, 1288
Gran, C., 1784
Green, M., 1013
Green, T. A., 474
Greenberg, D., 1005
Greenblatt, R. M., 376, 1527
Grésenguet, G., 1090
Gretch, D. R., 397
Griffin, G. E., 283, 1199, 1207, 1463
Grimminger, F., 191
Gringeri, A., 311
Grisetti, S., 1077
Grogan, J. L., 260
Groll, A. H., 274
Gross, R., 766
Grovit-Ferbas, K., 1247
Guderian, J., 224
Guderian, R. H., 1199
Guerrant, R. L., S97, S134
Guerrero, M. L., 1602
Guevara, A., 1199, 1207
Gulick, R. M., 1375
Guo, X., 1473
Gupta, K., 1177
Gupta, P., 79
Guth, P. H., 799, 808
Gutmann, L., 112
Guttormsen, H.-K., 1129
Guzman, G., 570
Gwinn, M., 330
Ha, E., 359
Haagsman, H. P., 917
Haarbrink, M., 564
Haber, M., 1218
Hack, C. E., 206
Hadler, S. C., 6
Hafiz, R., 6
Hahn, B., 1272
Haikala, R., 1146
Halasz, R., 1756
Halburnt, L. L., 1331
Hall, A. J. H., 1234
Hall, B. F., 1486
Halperin, S. A., 174
Hamann, D., 451
Hamel, J., 848
Han, A., 474
Han, S. N., S74
Han, X., 12
Hang, L., 1738
Hanski, E., 1702
Hanson, C., 1243
Hanson, D. L., 611
Hardy, D., 1070
Harrison, T. S., 283
Hart, C. A., 363
Hart, C. E., 1051
Haruta, A., 882
Haslett, P., 1357
Hatch, B., 941
Hatzakis, A., 590
Haubrich, R., 1375
Havlir, D. V., 321, 1658
Hawes, S. E., 540
Hay, P., 792
Hayes, R. J., 1090
Hayward, A. R., 1001
Heard, I., 112
Hedlund, K.-O., 678
Heesemann, J., 1268
Hegemann, J. H., 1678
Hellmann, N. S., 330
Helmerking, M., 509
Henderson, I. R., 1780
Heneine, W., 330
Hennessey, K. A., 6
Henrard, D., 1243
Henriksen, S. J., 725
Henriques, B., 833, 840
Herndon, J. G., 1051
Herold, K. M., 1311
Heuer, K. U., 191
Heuvelman, K., 1402
Heyder, A. M., 970
Heymann, J. J., 766
Hibble, M., 1109
Hib Vaccine Evaluation Team, 1553
Hickman, M. E., 1129
Higgins, T. J., 1304, 1311
Higgs, E. S., S1
Hill, A. B., 1051
Hill, H. R., 974
Hills, N. K., 595
Hillyer, G., 1243
Hino, S., 1511
Hirsch, M. S., 1357
Hirschel, B., 334
Hirst, R., 1749
Hjelle, B., 43
Ho, S. B., 882
Hoe, N. P., 1425
Hofmann, C. M., 1595
Hoiby, E. A., 133
Hollenstein, U., 343

Hollingshead, S. K., 1694
Holmes, J. L., 685
Hombach-Klonisch, S., 191
Homoncik, M., 343
Hoogerhout, P., 923
Hooton, T. M., 1177
Horibe, K., 937
Horn, D. L., 1731
Hoshika, T., 1511
Hoshino, Y., 937
Hossain, M. J., 391
Hossler, P. A., 551
Hostetter, M. K., 497
Hot, D., 1222
Houghton, J.M., 856
Hovi, T., 1
Hu, C. M., 1455
Hu, M., 1425
Hu, S., 200, 983
Hu, X. J., 1375
Huang, L., 1192
Huang, W., 1425
Hubbard, N. E., S5
Hughes, D. A., S11
Hughes, J. P., 1097
Hughes, M. D., 1385
Huitron-Resendiz, S., 725
Hultin, L., 1625
Hunsmann, G., 716
Hunter, M. J., 1272
Hunter, P. R., 380
Hurley, A., 945
Hurwitz, E. S., 1218
Hwang, J. Y., 1658
Ibarra, J., 1005
Iitsuka, T., 1511
Illiovich, E., 1523
Imami, N., 792
Imamichi, H., 1063
Imaoka, K., 180
International Interleukin-2 Study Group, 428
Ioannidis, J. P. A., 965
Isaacson, J., 420
Israel, R. J., 326, 1774
Iwai, H., 1103
Izumo, S., 1343
Izzo, M. W., 1109
Jackson, D., 1417
Jacobson, J. M., 326
Jacobson, L. P., 928, 1809
Jacobson, M. A., 1070
Jacobson, R. M., 1005
Jacobson, S., 1321
Jafari, H., 6
Jaffe, J., 1702
Jahn, H.-U., 1678
Jallow, O., 1545
Jantos, C. A., 1678
Jäntti, V., 1146
Jarvis, W. R., 474
Jarzecka, K., 671
Jason, J., 474
Jeanne, I., 405
Jen, S., 224
Jenkins, F. J., 928, 1809
Jerrells, T. R., 482
Jerse, A., 848
Jiang, X., 1519
Jilma, B., 343
Johansson, B., 49
Johnson, J. E., 1029
Johnson, P. A., 1286
Johnson, T. R., 1029, 1288
Jolly, C. A., S103
Jones, G., 1357
Jones, J. L., 611
Jongsakul, K., 371
Jordan, I., 1214
Jordens, R., 260
Jorup, C., 840
Joubert, M., 405
Journot, V., 599
Joyner, J. L., 974
Juffermans, N. P., 888, 902
Juhn, S. K., 882
Julander, I., 840
Jülch, C., 367
Jumaan, A. O., 383
Justement, S. J., 1804
Kaczmarski, E. B., 1557
Kahlert, C., 1810
Kahn, J., 1357
Kahn, J. S., 1228
Kai, O., 252
Kaji, S., 1511
Kalelkar, M. B., 1183
Kalin, M., 833, 840
Kalish, L. A., 603
Källenius, G., 833
Kampmann, B., 895
Kanki, P. J., 467, 1350
Kaplan, G., 640
Kaplan, J. E., 330, 611
Karch, H., 1540
Karron, R. A., 1331
Kasper, D. L., 1129
Katz, J., 551
Katz, R., 1109
Katzenstein, D., 1375
Katzenstein, T. L., 744
Kaup, F.-J., 716
Kawamura, Y., 1549
Kawano, H., 882
Kay, P., 1239
Kayentao, K., 993
Käyhty, H., 1146
Kazanjian, P., 551
Kazatchkine, M. D., 112
Kazembe, P. N., 474
Keen, C. L., S108
Kennedy, M. W., 1207
Kercher, L., 652
Kertesz, D. A., 168
Kessler, H., 321
Ketas, T. J., 326, 945
Ketter, N., 1357
Keundjian, A., 624
Keur, I., 1291
Keusch, G. T., S139
Khan, A. A., 356
Kilpi, T. M., 1146
Kim, Y., 882
Kimani, J., 459
Kimura, H., 937
Kimura, Y., 391
King, C. L., 558
King, J., 1694
King, L. E., S16
Kingsley, L. A., 79, 928
Kirk, O., 744
Kirstein, L. M., 1084
Kiss, L., 191
Kiviat, N. B., 1097
Kiyono, H., 180
Klauenberg, U., 367
Klein, M. B., 200
Kline, M. W., 1385
Klotman, M. E., 326
Klucken, A. C., 1678
Knol, G. J., 451
Knowles, M., 420
Knox, K. A., 620
Koech, D., 558
Koedel, U., 978, 1437
Koelle, D. M., 662
Kohler, S. M., 545
Kohno, T., 1722
Kojima, S., 937
Kolk, A. H., 902
Kollaritsch, H., 1005
Konaré, A., 993
Koning, F., 260, 570
Korah, R. M., 856
Kordari, P., 1425
Kornblum, J., 359
Kortok, M., 252
Kosek, J. C., 865
Kosek, M., 865
Koster, F., 43
Kostman, J. R., 766
Kousoulas, K. G., 928
Koutsky, L. A., 1097
Kovacs, A., 1385, 1527, 1616
Kovacs, C., 123
Kovacs, J. A., 428, 1063
Koyama, H., 1276
Krasinski, K., 359
Krawczak, M., 716
Kreiswirth, B. N., 359
Kremsner, P. G., 260, 988, 1570
Kress, Y., 1791
Kriss, J. A., 1039
Kristinsson, K. G., 1153
Krogstad, P., 751
Krowka, J., 1284
Krüll, M., 1678
Kublin, J. G., 993
Kuhn, L., 104
Kuijper, E., 1788
Kulka, K., 79
Kumar, P. N., 603
Kundu, S., 1357
Kuo, Y.-H., 112
Kuppermann, B. D., 1234
Kura, F., 1276
Kurazono, H., 180
Kuritzkes, D., 1357
Kusters, J. G., 1566
Kuter, B., 1005
Kuypers, J. M., 1097
Kuzushima, K., 937
Kweon, M.-N., 180
La Brooy, J., 1749
LaClaire, L., 1553
Lafon, M.-E., 36
Lagakos, S. W., 1375
Lager, B., 1756
Lagergren, Å., 678
Lal, A. A., 960
Lam, N. P., 28
Lambert, G., 104
Lambert, L., 1063
Lambert, V., 1222
Landesman, S., 1084
Landini, M. P., 1610
Lane, H. C., 428, 435, 1063
Lanningham-Foster, L., S81
Laosakkitiboran, J., 1652
La Pine, T. R., 974
Larson, A. M., 397
Larsson, C., 142
Lau, J. Y.-N., 1214
Lauw, F. N., 206
Lavarello, R., 865
Lawoko, A., 49
Layden, T. J., 28
Lazzarin, A., 311, 950, 1579
Lazzarotto, T., 1610
Leakey, A., 1749
Leavitt, R., 733
Lechner, F., 978
Ledergerber, B., 1540
Lee, C.-H., 551, 799, 808
Lee, S., 96
Lee, S., 517
Lee, S., 1192
Lee, S.-K., 1097
Lee, T.-H., 442
Lefèvre, J.-C., 1394
Leib, S. L., 347
Leigh, J., 1479
Lell, B., 1570
LeMonte, A. M., 545
Lemos, E. M., 634
Leppert, D., 347
Lermark, G., 133
Leroux, C., 79
Lescano, A. G., 865
Lett, S. M., 1409
Levander, O. A., S93
Levin, M., 895

Levine, M. M., 302, 1199
Levine, O. S., 1553
Levitz, S. M., 283
Levy, D., 1192
Levy, J. R., 1588
Lew, J., 1243
Li, B.-W., 1796
Li, N.-Q., S29
Li, Y., 1222
Liang, F. T., 1455
Lichtner, M., 1536
Lie-A-Ling, M., 1566
Liftis, F., 1796
Lima, A. A. M., S97, S134
Lin, H.-M., 1473
Lin, J., 882
Lindahl, G., 142
Lindsey, J. C., 1385
Lipkin, W. I., 1214
Little, S., 945
Liu, M., 1425
Liu, Q., 18
Liu, W., 1234
Liuzzi, G., 1077
Ljunggren, J., 49
Lobet, Y. N., 1455
Lobos, E., 1796
Locarnini, S. A., 941
Lokensgard, J. R., 983
Looareesuwan, S., 629
López, R., 1523
Losonsky, G., 302, 1199
Louie, L. G., 311
Lovgren, M., 168
Løvhaug, D., 1784
Low, D. E., 1425
Lowe, B. S., 252
Lowy, I., 326
Lu, H., 1672
Luketic, V. A., 1595
Lundgren, J. D., 744
Lundholm, S., 1756
Lunn, P. G., S23
Luo, C.-C., 330
Luo, J., 1473
Luo, M., 1672
Luscher, M. A., 123
Luty, A. J. F., 1570
Luz, Z. M. P., 634
Lyberg, T., 133
Maasho, K., 570
Mabey, D. C. W., 1090, 1545
MacDonald, K. S., 123
Maddon, P. J., 326, 1774
Madrazo-de la Garza, A., 1450
Maeda, N., 1276
Maguiña, C., 865
Maguire, J. H., 997
Mahdi, O. S. M., 1545
Maine, G. T., 1610
Malhotra, I., 558
Malkin, J.-E., 112
Mallqui, V., 865
Malmvall, B., 49
Maloney, E. M., 590
Mamani, N., 1519
Mancino, G., 776
Mani, I., 1350
Marais, D. J., 1239
Marchant, C. D., 1409
Marchetti, G., 639
Margolick, J. B., 1636
Margolis, H. S., 12
Margolis, T. P., 1234
Margraf, S., 643
Marinic, K., 1523
Markowitz, M., 945, 950
Marmor, M., 1284
Marques, A. R., 1006
Marrie, T. J., 833, 840
Marsh, K., 252
Marsik, C., 343
Martin, D., 848
Martin, D. F., 1234
Martinez, J., 359
Martino, P., 376
Marx, A., 6
Marx, P. A., 708
Marzi, M., 1536
Masci, A. M., 1365
Mask, C. A., 1183
Mason, H. S., 302
Massad, L. S., 1084
Massetti, A. P., 1536
Massung, R., 616
Mastrantonio, P., 1575
Mastro, T. D., 1652
Mastroianni, C. M., 1536
Masur, H., 1063
Mathema, B., 359
Mathews, A., 1326
Mathiesen, L. R., 744
Mathieson, B. J., 579
Matos, J., 1531
Matson, D. O., 1519, 1602
Matsuda, R., 1511
Matta, M., 1090
Maupin, G. O., 616
May, J., 1570
Mayaud, P., 1090
Mayer, L. W., 1169
Mazabel, E., 420
Mazur, M. H., 1005
Mazzotta, F., 1365
Mbopi-Kéou, F.-X., 1090
Mboup, S., 467
McAuliffe, V., 733
McCaw, R. F., 941
McClure, H. M., 1051
McCruden, E. A. B., 1515
McCullough, F. S. W., S23
McElhiney, S. P., 1311
McElrath, M. J., 1357
McFarland, E. J., 1616
McFarland, H. F., 1321
McGhee, J. R., 180
McGuirk, P., 1286
McIndoo, E. R., 1117
McIntosh, K., 96
McIntyre, L. M., 1251
McKenzie, P., S115
McKeon, B., 79
McKinney, R. E., 1385
McLauchlan, J., 923
McLellan, D., 1425
McMurray, D. N., S103
McNamara, J., 1769, 1774
Mearns, G., 1796
Medina, E. A., S5
Mednick, A., 1791
Mehlotra, R. K., 558
Mehrotra, D., 950
Mehta, S. K., 1761
Melnick, S., 1527
Melvin, A. J., 1616
Mendez, H., 1243
Meng, G., 785
Meng, Y.-X., 928
Mengoni, F., 1536
Merel, P., 36
Merigan, T. C., Jr., 1357
Merville, P., 36
Meshnick, S. R., 551
Metcalf, J. A., 1063
Mevius, D., 816
Meydani, S. N., S74
Meyer, C. G., 1570
Meyer, P. A., 383
Mican, J.A., 435
Michael, N. L., 311, 1579
Midathada, M., 474
Middleton, T. V., 941
Miedema, F., 451
Miguez-Burbano, M. J., S69
Mika, B. P., 28
Miller, J. E., 933
Miller, Y., 1417
Mills, C., 1375
Mills, K. H. G., 1286
Mills, P. R., 1515
Milwee, S., 970
Miner, R. C., 1765
Minkoff, H., 1084
Misore, A., 960
Mitchell, B. M., 652
Mitchell, D. B., 671
Mitsuyasu, R. T., 428, 1357
Mobbs, K. J., 363
Mofenson, L. M., 1243, 1769
Mohan, K. M., 1616
Molina, J.-M., 599
Molteni, C., 639
Monforte, A. D'A., 1077
Monroe, S. S., 685
Montana (Agence Nationale de Recherches sur le SIDA 091) Study Group, 599
Montaner, L. J., 766
Montaño, M., 1473
Montelaro, R., 79
Montelibano, C., 1497
Monterroso, E. R., 1588
Mooi, F., 1402
Moonis, M., 766
Moore, E. C., 766
Moore, J. M., 960
Moore, J. P., 945
Moore, P. S., 306
Moore, S. R., S97
Mootsikapun, P., 316
Moreira, M. C., 634
Morfin, F., 290
Mori, I., 391
Morishima, T., 937
Moriwaki, H., 1103
Morlat, P., 599
Morrow, A. L., 1602
Mortier, D., 1291
Mosci, P., 824
Moscicki, A.-B., 595
Moser, C. A., 1039
Moses, A. E., 1702
Mosnier, J.-F., 1222
Mosteller-Barnum, M., 785
Motta, P., 1523
Moukassa, D., 1222
Moye, J., 1385, 1774
Mozzato-Chamay, N., 1545
Mueller, N., 379
Mufson, M. A., 833, 840
Mugerwa, R., 1350
Mugyenyi, P., 1350
Mühl, T., 716
Müller-Myhsok, B., 367
Multicenter Hemophilia Cohort Study, 590
Multilobar Pneumonia Study Group, 970
Mungai, P., 558
Muñoz, O., 1450
Murakami, J., 1511
Muratori, S., 311
Murph, J. R., 933
Murphy, B. R., 1331
Murray, H. W., 1497
Murri, R., 1077
Mushahwar, I. K., 294
Musher, D. M., 158
Musser, J. M., 517, 1425
Muto, Y., 1103
Nabors, G. S., 1694
Nachman, S., 96
Naficy, A. B., 685
Nagaki, M., 1103
Nagata, I., 1511
Nagata, Y., 799, 808
Nagelkerke, N. J. D., 459
Nahlen, B. L., 960
Nahm, M. H., 1694
Naiki, T., 1103
Nainan, O. V., 12
Nair, G. B., 1161

Nakagawa, M., 595, 1343
Nakatani, K., 1549
Naoe, S., 1183
Nardin, E. H., 1486
Narita, N., 1664
Natanson-Yaron, S., 1702
Nataro, J. P., 1780
Nathanson, N., 579
Navin, T. R., 1192
Nazzal, D., 1394
Ndungu, F., 252
Nelson, S., 970
Nesheim, S. R., 104
Neto, R. B. F., 1463
Neumann, A. U., 28
Newbold, C. I., 252, 629
Ngugi, E. N., 459
Nguti, R., 1672
Nicastri, E., 1574
Nicholson, W. L., 616
Nielsen, C., 744
Nielsen, H., 744
Nielsen, K., 751
Nigou, J., 240
Nijhuis, M., 59
Nilsson, M., 678
Nixon, D. F., 88, 766
Nizet, V., 150, 824
Nociari, M. M., 1712
Nofchissey, R., 43
Nogueira, A. M. M. F., 1008
Noonan, D. M., 1643
Nootenboom, I. C., 1566
Norman, J. E., 1583
Norrby, S. R., 1005
Northrop-Clewes, C. A., S23
Nousbaum, J.-B., 397
Novembre, F. J., 1051
Nussenzweig, R. S., 1486
Nutman, T. B., 1199, 1207, 1796, 1804
Nwanyanwu, O. C., 474
Nylén, S., 570
Obel, N., 744
O'Brien Gress, J., 1005
Ochs, H. D., 435
Offit, P. A., 1039
Ohnishi, H., 1103
Okamoto, M., 1511
Okamoto, Y., 1664
Okamura, H., 1664
Okayama, A., 379
Øktedalen, O., 1784
Oliveira, G. A., 1486
Oliveira, R. B., 1463
Olivier, M., 240
Olsen, S. J., 306
Olson, W. C., 326, 1774
Olsson, J., 1625
Olsson Liljequist, B., 833
Olszyna, D. P., 1264, 1731
O'Neil, S. P., 1051
O'Neill, T. J., 326
Ono, M., 607
Ooka, T., 290
Opal, S. M., 1731
Orefici, G., 824
Orenstein, J. M., 338
Orman, K. L., 1561
Orr, A., 1515
Ortiz, G. M., 766
Örtqvist, Å., 833, 840
O'Ryan, M. L., 1519
Osame, M., 1343
Osborn, K. G., 725
Osterhaus, A. D. M. E., 923
Ostrowski, M., 1804
Otto, M., 1688
Ouellet, L. J., 1588
Ouellet, N., 1255
Ouma, J., 558
Ovendale, P. J., 224
Pachuk, C. J., 1304, 1311
Paglia, M. G., 1077
Palefsky, J. M., 595, 1084
Palumbo P. E., 104, 413
Palzkill, T., 1425
Pancholi, P., 18
Pancholi, V., 1712
Pankhurst, J. L., 941
Pantaleo, G., 311
Paoletti, L. C., 1129
Papasavvas, E., 766
Para, M. F., 59, 733
Pardo, A., 1473
Parenti, D., 1005
Park, M. K., 1694
Parkinson, A. J., 490
Parks, D. J., 490
Patel, S., 595
Patick, A. K., 420
Paton, J. C., 1146
Patterson, B. K., 79
Pau, C.-P., 330
Paul, J.-L., 1090
Paul, R., 1437
Pedersen, C., 744
Pediatric AIDS Clinical Trials Group, 1616
Pediatric AIDS Clinical Trials Group 338 Study Team, 96
Pediatric AIDS Clinical Trials Group Protocol 351 Study Team, 1774
Pedral-Sampaio, D., 1531
Pedroso, C., 1531
Peebles, R. S., Jr., 671, 1288
Pellegrin, I., 36
Pellett, P. E., 928
Pelton, S., 96
Peña, A., 1519
Peppelenbosch, M. P., 888
Perelson, A. S., 28
Perinatal AIDS Collaborative Transmission Study (PACTS), 104
Perkins, B. A., 1169
Perkins, D. J., 988
Perkus, M. E., 18
Perrin, L., 334, 950
Peterson, G., 970
Peterson, G. E., 1251
Peterson, P. K., 983
Peterson, R., 1497
Petheram, S. J., 933
Petraitiene, R., 274
Petraitis, V., 274
Petropoulos, C. J., 330, 758
Petru, A., 1616
Pettinelli, C., 1375
Pfister, H. W., 1437
Pfister, L.-A., 347
Phan, H. M., 158
Philipp, M. T., 1455
Phillips, A. N., 334
Phillips, T. R., 725
Piantedosi, R., S97
Pichichero, M. E., 1425
Pickering, L. K., 1602
Pieniazek, N., 1192
Pierson, D. L., 1761
Pierson, T. C., 1636
Piirainen, L., 1
Pipkorn, R., 49
Piscitelli, S. C., 274
Pitt, J., 1243
Plaeger, S., 751, 1247, 1357
Plancoulaine, S., 405
Plante, M., 848
Plikaytis, B. D., 1169
Plowe, C. V., 993
Plummer, F. A., 459, 1672
Poland, G. A., 1005
Poles, M., 1625
Poli, G., 311, 1579
Polis, M. A., 1063
Pollack, H., 88
Pollard, R. B., 321
Polley, A. C. J., S11
Polyak, S. J., 397
Popovic, T., 1169, 1402
Portales, P., 1285
Porter, D. D., 1326
Powderly, W., 955
Prasad, A. S., S62
Prazuck, T., 112
Preiser, W., 643
Prieto, S., 1519
Prince, A. M., 18
Prince, G. A., 1326
Prins, J. M., 206, 1731
Puissant, B., 1394
Pukrittayakamee, S., 629
Puliti, M., 824
Puzo, G., 240
Qu, L., 1013
Quadro, L., S97
Quinn, T. C., 1636
Quint, W., 1291
Quyyumi, A. A., 1583
Rabodonirina, M., 381
Racioppi, L., 1365
Radding, J., 88
Raffi, F., 599
Ramaswamy, S., 517
Ramjee, G., 1239
Ramos, P. K. S., 997
Rancinan, C., 599
Randolph, V. B., 1331
Rao, M. R., 685
Rapola, S., 1146
Raskino, C., 413
Rathore, M., 1774
Ravins, M., 1702
Ray, S. C., 698
Razsi, D., 474
Read, J. S., 1616
Read, R. C., 1557
Reasonover, A. L., 490
Recavarren, S., 865
Reed, G. W., 1331
Reed, S. G., 224
Reeves, M. W., 1169
Reichman, R. C., 316
Reis, M. G., 1800
Reisinger, K., 1005
Remington, J. S., 356
Rench, M. A., 1129
Renjifo, B., 1531
Respess, R., 330
Revill, P. A., 941
Rey, L., 1222
Reyes, J., 1013
Reynes, J., 1285
Rezza, G., 1809
Rich, K. C., 1243
Richardson, J., 551
Richman, D. D., 321, 945
Riehman, M., 359
Rigaud, M., 88
Rimland, D., 1192
Rinaldo, C. R., Jr., 79, 928
Rinder, H., 1788
Ring, A., 150
Ringwald, P., 624
Rioux, C. R., 848
Riquelme, R., 840
Rizzardi, G. P., 311
Robbins, J. B., 1576
Roberts, P. L., 1177
Robertson, M., 950
Robinson, C. A., 1616
Rocchi, G., 776
Rocha, A. M. C., 1008
Rocha, G. A., 1008
Rochette, L., 174
Rodrigues, L. C., 1800
Rodriguez, M. E., 1139
Rogers, P. D., 1280
Rogers, T. S., 785
Roivainen, M., 1
Rojas, M., 240

Rolles, K., 1610
Rolli, M., 376
Romero, J. R., 298
Romero-Steiner, S., 1553
Roos, M. T. L., 451
Root, R., 970
Rosandich, M., 1357
Rose, F., 191
Rose, R. C., 1239
Rosenberg, H. F., 1022
Rosenberg, M., 88
Rosenstein, N. E., 1169
Rosenthal, K. L., 123
Ross, A., 252
Ross, A. C., S29
Ross, R. K., 1300
Rosseau, S., 1678
Rossi, M. C., 639
Rotbart, H. A., 298
Rothenbacher, D., 1446
Rowe, D., 1013
Rowe, M., 1005
Rowley, A. H., 1183
Rozenbaum, W., 599
Rudolph, K. M., 490
Ruiz-Palacios, G. M., 1602
Ruscio, M., 1455
Russo, G., 1536
Rutherford, J., 459
Rutherford, J. S., 616
Ryan, E. J., 1286
Rydèn, C., 351
Saavedra, M., 955
Sabin, C. A., 1610
Sabundayo, B. P., 1636
Sacchi, C. T., 1169
Sack, D. A., 1161
Sack, R. B., 1161
Saenz, H. L., 1688
Saetre, T., 133
Saha, M. N., 1161
Sahrbacher, U., 978
Saisorn, S., 371
Sakolvaree, Y., 371
Salazar, M. A., 1473
Salcedo, M., 526
Sá-Leão, R., 1153
Sällberg, M., 1756
Salmi, D. B., 1117
Salvayre, R., 1394
Sampaio, E. P., 1463
Sampson, J. S., 1146
Samson, P., 1774
Samten, B., 234
Sanches, I. S., 1153
Sanchez, J., 1553
Sandberg, J. K., 766
Sanden, G., 1402
Sandoval, C., 1199, 1207
Sanna, R., 1291
Santagostino, E., 311
Santos, C. A. S. T., 1800
Santos, R. S., 997
Sanyal, A. J., 1595
Saravolatz, L. D., 428
Sarid, R., 306
Sarmati, L., 1574
Sasaki, M. G., 1531
Satti, I., 570
Saucier, M., 1051
Sauermann, U., 716
Savarino, S. J., 685
Scapini, P., 1643
Scaramuzzino, D. A., 1109
Schapiro, J. M., 59
Schauer, D. B., 620
Schellekens, P. T. A., 451
Schiller, D., 945
Schlauder, G. G., 294
Schleif, W. A., 758
Schlotmann, T., 367
Schmeckpeper, B., 1486
Schneeberger, P. M., 1291
Schneerson, R., 1576
Schnizlein-Bick, C., 545
Schoenbaum, E. E., 104
Scholes, D., 1177
Scholz, H., 509
Schomogyi, M., 662
Schooley, R. T., 1357
Schrier, R. D., 1658
Schrive, M.-H., 36
Schubert, S., 1268
Schuchat, A., 1417
Schultz, M. J., 1264
Schwartz, D. A., 1652
Scott, M., 595
Seeger, W., 191
Sekine, I., 1549
Sellers, M. T., 785
Selman, M., 1473
Selway, D. R., 725
Semba, R. D., 1084
Sentinel Health Unit Surveillance System Site Coordinators, 168
Senzilet, L. D., 168
Sereni, D., 599
Sevin, A. D., 59
Seward, J. F., 383
Seybold, J., 1678
Seymour, L., 1260
Shadmani, R., 174
Shaffer, N., 1652
Shankar, A. H., S37
Shattock, R. J., 1463
Shaver, A., 1616
Shaw, G. M., 785
Shaw, J. J., 997
Shaw, M. L., 1515
Shearer, W. T., 1774
Sheehy, M. E., 88
Sheller, J. R., 671
Shen, C., 1672
Shenep, J. L., 150
Sheng, W. S., 983
Sheppard, H. W., 311, 1579
Shetzigovski, I., 1702
Shiffman, M. L., 1595
Shiraki, K., 1511
Shivaprakash, M., 758
Shope, T., 1218
Shopsin, B., 359
Shor-Posner, G., S69
Shouval, D., 1005
Shroff, K. E., 1311
Shull, J., 766
Shulman, S. T., 1183
Shults, J., 1602
Shum, C., 1234
Sibelius, U., 191
Sibley, D., 482
Sieder, A., 343
Siegel, J. P., 435
Sigal, L. H., 534
Siliciano, R. F., 1636
Silva, M. R. B., 997
Silva, R. C. R., 1800
Sim, M.-S., 751
Simard, M., 1255
Simmons, S. S., 1005
Si-Mohamed, A., 112
Simonsen, J. N., 459
Simpson, A. J. H., 206
Simpson, J. A., 629
Sinei, S., 1672
Sipe, P. L., 1409
Skeiky, Y. A. W., 224
Slavinsky, J., III, 955
Slifer, T. R., 356
Smaill, F. M., 123
Smeaton, L., 321
Smedema, M. L., 545
Smith, B. L., 497
Smith, D., 950
Smith, I. L., 1616
Smith, P. D., 785
Smith, S. M., 708
Smolskis, M., 428
Snelier, M., 435
Snewin, V. A., 895
Snyder, S., 733, 1375
Sohnle, P. G., 1272
Soldan, S. S., 1321
Sommadossi, J.-P., 321
Sonnenberg, M. G., 1722
Sookoian, S., 294
Sopper, S., 716
Sorrentino, A., 1523
Souillet, G., 290
Southon, S., S11
Speciale, L., 1365
Spector, S. A., 413, 1616, 1769
Speelman, P., 888, 902, 1731
Spetz, A.-L., 1625
Spiegel, H. M. L., 88
Spika, J. S., 168
Spino, C., 1357
Sporer, B., 1437
Spoulou, V., 965
Spring, M., 716
Sridhara, R., 1199
Sriprakash, K. S., 1109
Stahl-Hennig, C., 716
Stålhammar-Carlemalm, M., 142
Stamm, W. E., 540, 909, 1177
Stankowiak, C., 1222
Stanley, K., 96
Stantchev, T. S., 68
Stapleton, A. E., 1177
Staprans, S., 1774
Starr, S. E., 1769, 1774
Steel, C., 1796
Steele, C., 1479
Stempien, M. J., 1616
Stenvik, M., 1
Stephens, D. S., 1417
Sterling, R. K., 1595
Stevens, D. L., 799, 808, 1117
Stevens, R., 1063
Stewart, C. A., 1595
Stiles, J. K., 1280
Stites, D. P., 595
Stobberingh, E., 816
Stohlawetz, P. J., 343
Stolte, N., 716
Stone, J., 970
Stowe, R. P., 1761
Strasser, J. E., 1304
Stremmel, W., 150
Sturm-Ramirez, K., 467
Stuver, S. O., 379
Suchland, R. J., 540, 909
Sun, J., 766
Sungkarat, S., 1652
Supapol, W., 1652
Suter, T., 978
Sutter, R. W., 6
Suttorp, N., 1678
Suwyn, C., 1051
Suzuki, K., 1276
Svanborg, C., 1738
Svenson, S. B., 833
Svensson, L., 678
Svenungsson, B., 678
Swanstrom, R., 1375
Swift, A., 1694
Swiss HIV Cohort Study, 1540
Swoboda, R., 955, 1479
Sypek, J. P., 1497
Syrjänen, R., 1146
Tacchetti, C., 1643
Tacket, C. O., 302
Tahar, R., 624
Takahashi, I., 180
Takahashi, K., 1183
Takala, A. K., 1146
Takano, Y., 1276
Takeda, Y., 180, 1161
Takenaka, H., 1664
Takeshita, S., 1549

Talarmin, A., 405
Talbot, J. A., 168
Tamaki, S., 1664
Tapia, M., 751
Täuber, M. G., 347
Tavares, D., 266
Taylor, B. N., 955
Taylor, C. E., S1
Taylor, K. A., 974
Taylor, N. S., 620
Taylor, R. N., 376
Tazawa, Y., 1511
Tellado, J. M., 526
Tennfjord, V.-A., 1784
Tenover, F., 1417
Teo, S. T., 1218
Terai, M., 1183
Terhell, A. J., 564
Thalme, A., 840
Thomas, D. L., 698
Thomas, K. K., 1097
Thompson, J., 1331
Thompson, M., 1616
Thomsen, M., 1394
Thomson, A. P. J., 363
Thorpe, L. E., 1588
Thouvenot, D., 290
Thumar, B., 1331
Thurnham, D. I., S23
Tierney, C., 321
Timmermans, H. A. M., 923
Tissi, L., 824
Tobian, A. A. R., 558
Tomasz, A., 1153
Tomnay, J., 941
Tondella, M. L. C., 1169
Top, J., 816
Torres, A., 833, 840
Torres, J., 1450
Torriani, F. J., 1658
Tortevoye, P., 405
Trabattoni, D., 639
Tran, D. N. H., 326
Tricoche, N., 18
Trimoulet, P., 36
Trkola, A., 326, 945
Trollfors, B., 1576
Truong-Tran, A. Q., S85
Tsuge, I., 937
Tsujimoto, H., 1549
Tsukaguchi, K., 1664
Tsurumi, T., 937
Tung, H.-S., 351
Twadell, T., 1357
Tyring, S. K., 1761
Tyrrell, G. J., 168
Uccella, I., 776
Udem, S. A., 1331
Udhayakumar, V., 960
Udomsangpetch, R., 629
Uherova, P., 1357
Uhnoo, I., 678, 1005
Urban, J. F., Jr., 1207
Usuku, K., 1343
Valassina, M., 1577
Valentine, F. T., 1357
Valtanen, S., 1
van Baarle, D., 451
van Belkum, A., 816
Van Damme, P., 1005
van den Biggelaar, A. H. J., 260
van den Bogaard, A., 816
van den Braak, N., 816
Vandenbroucke-Grauls, C. M. J. E., 1566
van den Hoven, H., 1291
van der Heijden, T. G., 1291
van der Kooi, A., 923
van der Pol, W.-L., 1139
van der Poll, T., 206, 888, 902, 1264, 1731
van Deventer, S. J. H., 206, 888, 902, 1264, 1731
van de Winkel, J. G. J., 917, 1139
van Doorn, H. R., 1788
van Doorn, L.-J., 1291
van Embden, J. D. A., 816
van Fenema, E. M., 983
van Hamersvelt, H. W., 1291
van Haperen, A. V.-, 1291
van Hattum, J., 1005
Vanhems, P., 334
Vankayalapati, R., 234
van Lier, R. A. W., 451
van Loon, A. M., 1291
van Rozendaal, B. A. W. M., 917
van Soolingen, D., 1788
van Spriel, A. B., 917
Vardas, E., 1239
Vargas, M., 1780
Vazquez, M., 1228
Vedvick, T. S., 224
Veglia, F., 311
Velázquez, F. R., 1602
Verástegui, M., 865
Verbon, A., 902, 1264
Verhoofstad, I., 451
Verjans, G. M. G. M., 923
Vernazza, P. L., 1810
Vicenzi, E., 311, 1579
Vichi, F., 1365
Victoratos, P., 965
Vidarsson, G., 1139
Vig, P., 428
Vignes, F. N. , 1409
Vila, J., 1780
Vilé, H. A., 1139
Vilhelmsson, S. E., 1153
Villa, C., 311
Villa, M. L., 1365
Villamor, E., S122
Vincent, R., 1350
Vink, P. E., 104
Viral Activation Transfusion Study Group, 603
Vithayasai, P., 442
Vithayasai, V., 442
Vizzard, J., 334
Voet, P. E., Jr., 1455
Vogel, J.-U., 643
Vogel, S., S97, 1063
Von Hagen, S., 856
von Hunolstein, C., 824
Vullo, V., 1536
Vuong, C., 1688
Vuopio-Varkila, J., 1425
Waase, I., 367
Waddington, M., 359
Wahl, M., 1005
Wain-Hobson, S., 1044
Walker, B. D., 1350, 1357
Walker, R. E., 1063
Walmsley, S. L., 123
Walsh, T. J., 274
Walter, E., 1005
Wamachi, A., 558
Wang, E., 1255
Wang, Q. J., 928
Wang, Y., 799, 808
Wara, D., 1774
Ward, J. W., 611
Warren, H. S., 873
Warwick-Davies, J., 1463
Washum, K. E., 545
Wasserman, R., 298
Watanabe, H., 1276
Watkins, A., 792
Watson, D. A., 158
Watson, J., 1070
Watt, G., 371
Wattel, E., 1044
Wattré, P., 1222
Webber, S., 1013
Weber, R., 950, 1540
Weedon, J., 104
Wei, L. S., 751
Weil, G. J., 1796
Weiland, O., 1756
Weinberg, J. B., 988
Weinstock, H., 330
Weir, S. C., 1006
Weis, S. E., 234
Weiss, H. A., 1090
Welch, W., 970
Wenner, W. J., 1039
Wennerholm, S., 1005
Westby, M., 792
Weynants, V. E., 1455
Wharton, M., 383
Wheat, L. J., 545
Whitby, D., 1574
White, N. J., 206, 629
Whitehead, S. S., 1331
Whitmore, J. B., 1531
Whitney, A. M., 1169
Whitney, C. G., 1417
Wierzba, T. F., 685
Wiley, D. J., 1247
Wiley, T. E., 28
Willems, R. J. L., 816
Williams, I. T., 1588
Williams, T., 629
Williamson, A.-L., 1239
Wilson, J. D. K., 792
Wise, J., 1610
Wittek, A. E., 1331
Wizel, B., 234
Wiznia, A., 88, 96
Wolbink, A. M., 206
Women and Infants Transmission Study (WITS), 1243
Wong, T. K., 607
Woodhead, M. A., 833, 840
Woods, T., 330
Wozniak, K., 955
Wray, D., 1251
Wright, A. J. A., S11
Wright, P. F., 1331
Wuppermann, F. N., 1678
Xu, J., 1616
Yamaguchi, N., 607
Yamamoto, M., 180
Yamamoto, S., 180
Yamashita, M., 1343
Yazdanbakhsh, M., 260, 564
Yeaman, M. R., 1251
Yih, W. K., 1409
Yogev, R., 96, 1616
Yoneda, T., 1664
Yong, F. H., 1769
Yoshimi, A., 937
Young, D. B., 895
Young, G. P., S85
Young, M., 1084, 1527
Young, V. B., 620
Yu, M. C., 1300
Yuan, J.-M., 1300
Zagliani, A., 1365
Zalewski, P. D., S85
Zbinden, R., 1540
Zeidner, N. S., 616
Zhang, B., 1357
Zhang, P., 18
Zhang, Q., 1260
Zhao, X., 517
Zhou, J., 517
Zhu, J., 1583
Ziermann, R., 758
Zimmerman, P., 558
Zolfaghari, R., S29

Subject Index

N-Acetylcysteine, in pneumococcal meningitis, rat model, 347
N-Acetyl-leucinyl-leucinyl-norleucinal, in pneumococcal meningitis, rat model, 1437
Acid, *Helicobacter pylori* growth in, loci essential for, 1566
Acquired immunodeficiency syndrome (*see* Human immunodeficiency virus infection [type 1 or unspecified])
Acyclovir, resistance to, herpes simplex virus type 1, 290
Adefovir, for human immunodeficiency virus infection, after indinavir failure, 1375
Adenosine diphosphate-ribosyltransferase, in streptococcal toxic shock syndrome, 1117
Adherence factors, enteroaggregative *Escherichia coli,* 1780
Adhesion
  pneumococci, choline-binding protein A in, 497
  Staphylococcus epidermidis, 351
Adhesion molecules
  amphotericin B action on, 1280
  junctional, antibodies to, in meningitis, mouse model, 978
Adoptive immune transfer, in cytomegalovirus retinitis, mouse model, 652
Agammaglobulinemia, enterovirus mutation rate in, over 7-year period, 298
agr quorum-sensing phenotype, *Staphylococcus aureus,* in biofilms, 1688
AIDS (*see* Human immunodeficiency virus infection [type 1 or unspecified])
Airway
  epithelial cells, *Chlamydia pneumoniae* infections, 1678
  hyperresponsiveness, in respiratory syncytial virus infections, mouse model, 671
Alanine aminotransferase, in chronic hepatitis C, 1595
Albendazole, in ascariasis, cholera vaccine response and, in pediatric patients, 1199
Alcohol use, in *Salmonella typhimurium* infections, mouse model, 482
Alzheimer's disease, *Borrelia* involvement in, 1006
American trypanosomiasis (Chagas' disease), treatment, long-term results, 634
Amphotericin B
  action on monocytes, 1280
  for histoplasmosis, 545
  lipid formulations, for candidiasis, central nervous system, rabbit model, 274
  for visceral leishmaniasis, mouse model, 1497
Amplicor tests, for cytomegalovirus, in kidney transplantation, 36
Amplified-fragment length polymorphism analysis, in *Enterococcus faecium* resistance, 816
Amprenavir, for human immunodeficiency virus infection, 758
Anemia, in malaria, transforming growth factor-β1 and, 988
Angiogenesis, in human immunodeficiency virus, transactivator protein in, 1643
Animal models
  antioxidants
    in influenza, mouse, S74
    in pneumococcal meningitis, rat, 347
  candidiasis
    central nervous system, treatment with amphotericin B lipid formulations, rabbit, 274
    in human immunodeficiency virus infection, mouse, 955
    resistance to, mouse, 266
Chlamydia psittaci shedding, 375
cryptosporidiosis immunity, mouse, 1001
cysteine-rich intestinal protein, mouse, S81
cytomegalovirus retinitis treatment, mouse, 652
gas gangrene, microvascular dysfunction, rat, 799, 808
Helicobacter pylori infections, gastric growth alterations in, mouse, 856
hepatitis A viremia, chimpanzee, 12
hepatitis C virus DNA vaccine, mouse, 18
herpes simplex virus type 2 vaccination, mouse and guinea pig, 1304, 1311
human immunodeficiency virus infection
  feline immunodeficiency virus, 725 (*see also* Simian immunodeficiency virus infection)
  progression, chimpanzee, 1051
immune effects of dietary fats, mouse, S54, S103
influenza pathogenesis, mouse, 391
intestinal endotoxin localization, rat, 873
Lyme disease serodiagnosis, mouse, 1455
meningitis pathogenesis, mouse, 978
mucoid otitis media pathogenesis, rat, 882
Neisseria gonorrhoeae vaccination, mouse, 848
neutrophil migration in sepsis, mouse, 214
pneumococcal infections
  meningitis treatment, rat, 1437
  pneumonia treatment, mouse, 1255
  vaccination, mouse, 1694
pulmonary infections in myeloperoxidase deficiency, mouse, 1276
pyelonephritis, mouse, 1738
respiratory syncytial virus infections
  cotton rat, 1326
  mouse, 671
  with pertussis toxin sensitization, mouse, 1029
Salmonella typhimurium infections, alcohol consumption and, mouse, 482
streptococcal cross-protection between serogroups, mouse, 142
streptococci group A
  mouse-passaged highly encapsulated variant, characterization, mouse, 1702
  toxic shock syndrome pathophysiology, pig, 133
streptococci group B β-hemolysin action, mouse, 150, 824
tetanus toxoid response in vitamin A deficiency, mouse, S29
tuberculosis
  interleukin-1 signaling in, mouse, 902
  skin-test improvement, mouse, 224
viral infections in malnutrition, mouse, S93
visceral leishmaniasis treatment, mouse, 1497
zinc deficiency, mouse, S16
Antibiotics *(see also specific antibiotics and diseases)*
  inflammatory response modification, in pneumococcal infections, 1561
Antibody(ies)
  antigen-specific, in Lyme disease, 534
  Bordetella pertussis, in vaccine evaluation, 1575
  human immunodeficiency virus, in highly active antiretroviral therapy, 945
  human papillomavirus, in human immunodeficiency virus infection, 1239
  in Lyme disease, 1455
  monoclonal

for lipopolysaccharide-bound monocyte detection, in gram-negative sepsis, 1549
for respiratory syncytial virus infections, cotton rat model, 1326
pneumococcal capsular polysaccharide, in vaccine studies, 158
pneumococci
in colonization, 1146
in vaccination, in infants, 1260
poliovirus, formation in vaccination, 1
rotavirus, as protection markers, 1602
streptococcal inhibitor of complement, 1425
streptococcal surface enolase, in rheumatic fever pathogenesis, 1712
Antibody card test, for onchocerciasis, 1796
Antigen-based AxSYM immunoassay, for cytomegalovirus, in liver transplantation, 1610
Antigen-presenting cells, in schistosomiasis, 260
Antimony compounds, for visceral leishmaniasis, mouse model, 1497
Antioxidants
in coxsackievirus infections, mouse model, S93
in influenza, S74
in malaria, S37
in pneumococcal meningitis, rat model, 347
Antiretroviral agents (*see* Highly active antiretroviral therapy; *specific agents*)
Apoptosis
epithelial cells, in zinc deficiency, S85
gastric cells, in *Helicobacter pylori* infections, mouse model, 856
leukocytes, in human immunodeficiency virus infection, 1536
macrophages, *Mycobacterium tuberculosis* in, 240
Artesunate, for malaria, parasite clearance and, 629
Arthritis, streptococci group B, severity, vs. β-hemolysin expression, mouse model, 824
Ascariasis
cytokine response in, 1207
treatment with albendazole, cholera vaccine response and, in pediatric patients, 1199
Aspergillus fumigatus, respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Asthma
pertussis morbidity in, 174
in respiratory syncytial virus infections, mouse model, 671
Astronauts, cytomegalovirus reactivation during spaceflight, 1761
Astrovirus, diarrhea, epidemiology, Egyptian children, 685
Ateviridine, for human immunodeficiency virus infection, resistance to, 316
Atherosclerosis
Chlamydia pneumoniae in, 1557
hepatitis A virus in, 1583
Autoimmune diseases, streptococcal, pathogenesis, 1712
AxSYM immunoassay, for cytomegalovirus, in liver transplantation, 1610

Bacillus Calmette-Guérin, vaccination, hookworm epidemiology and, 1800
Bacteremia
meningococcal, RANTES in, 363
neutrophil migration impairment in, mouse model, 214
pneumococcal
epidemiology, North America and Europe, 833, 840
prognosis, 840
treatment with filagrastim, 970
Staphylococcus aureus, resistance to platelet microbicidal proteins, 1251
streptococcal group B, epidemiology, Canada, 168
Bacterial vaginosis, human immunodeficiency virus infection susceptibility in, 467
Bacteriophage phiX174 immunization, for T cell evaluation, in human immunodeficiency virus infection, 435
Bartonella bacilliformis, infections, natural history, in nonendemic populations, 865
BAY 11-7085, in pneumococcal meningitis, rat model, 1437
B cells
rotavirus-specific, in lamina propria, 1039
zinc deficiency effects on, mouse model, S16
Beta-carotene
in influenza, S74
in malaria, S37
Biofilms
Staphylococcus aureus in, *agr* quorum-sensing phenotype, 1688
Staphylococcus epidermidis, 351
Blood-brain barrier, human T cell leukemia type I virus penetration, 1044
Bloodstream infections (*see* Bacteremia)
Bone marrow transplantation
herpes simplex virus type 1 resistance in, 290
lymphoproliferative disorder after, Epstein-Barr virus–associated, longitudinal dynamics, 937
pneumococcal vaccination in, in children, 965
Bordetella pertussis
infections
epidemiology, Massachusetts adolescents and adults, 1409
morbidity in, in adolescents and adults, 174
toxins
polymorphism in, 1402
sensitization with, respiratory syncytial virus infection pathogenesis in, 1029
vaccination, 1286, 1575
virulence factors, polymorphisms in, 1402
Borreliosis (*see* Lyme disease)
Botulism, epidemiology, at United States–Mexico border, 1503
Brain (*see also* Encephalitis; Meningitis)
Borrelia detection in, 1006
candidiasis, treatment with amphotericin B lipid formulations, rabbit model, 274
human T cell leukemia type I virus penetration, 1044
Brain stem auditory potentials, in feline immunodeficiency virus infection, acute morphine exposure effects on, 725
Bronchi, immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
Bronchiolitis, respiratory syncytial virus, treatment, cotton rat model, 1326
Brucellosis, epidemiology, at United States–Mexico border, 1503

cagA gene, *Helicobacter pylori*
genotypes, in Mexico, 1450
in pediatric patients, 1007
Calcium, in *Mycobacterium tuberculosis*–induced macrophage apoptosis, 240
Calicivirus, diarrhea, epidemiology, Chile, 1519
Calpain inhibitors, in pneumococcal meningitis, rat model, 1437
Calprotectin, recombinant, zinc-reversible antimicrobial activity, 1272
Canarypox virus, in hepatitis C virus vaccine preparation, mouse model, 18
Candida
infections
central nervous system, treatment, with amphotericin B lipid formulations, rabbit model, 274

in human immunodeficiency virus infection, mucosal, mouse model, 955
inhibition, oral epithelial cells in, 1479
innate defense against, pulmonary surfactant protein D in, 917
resistance to, mouse model, 266
virulence factors, in human immunodeficiency virus infection, mouse model, 955
Candida albicans
in growth inhibition assay, for calprotectin, 1272
respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Candida glabrata, respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Candida tropicalis, respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Carcinoma, hepatocellular, hepatitis G risk in, 1300
Cardiomyopathy, dilated, enterovirus persistence in, 1222
Carotenoids
in malaria, S37
in monocyte function, S11
Carriage (*see* Colonization)
Caspase, activation, in zinc deficiency, S85
Caspofungin, *Cryptococcus neoformans* cell wall glucan synthesis and, 1791
CD4-IgG2, recombinant, for human immunodeficiency infection, 326, 1774
CD40 ligand, response to, in human immunodeficiency virus infection, 776
CD44 molecule, amphotericin B action on, 1280
CD114 molecule, on neutrophils, endotoxin effects on, 343
Ceftriaxone, for pneumococcal pneumonia, mouse model, 1255
Cell cycle, of blood cells, zinc deficiency effects on, mouse model, S16
Cellular and Molecular Immunomodulatory Mechanisms workshop (Bethesda, MD, September 1999), Supplement 1
Cellular immune response
to antiretroviral therapy, for human immunodeficiency virus infection, 950
to *Ascaris lumbricoides,* 1207
to *Candida,* 1479
to herpes simplex virus type 2, 662
to human immunodeficiency virus, 474
in resistant persons, 123, 1810, 1811
in vaccination, 1350
to influenza virus, S74, 391
to mycobacteria, 474
evaluation, recombinant reporter mycobacteria for, 895
to *Mycobacterium tuberculosis,* 234
to *Plasmodium,* 367
to *Salmonella,* 474
to *Schistosoma,* 260
Central nervous system, candidiasis, treatment with amphotericin B lipid formulations, rabbit model, 274
Cerebrospinal fluid, human T cell lymphotropic virus type I in, 1044
Cervicitis, *Chlamydia trachomatis,* culture in, 540 (*see also* Herpes simplex virus, type 2)
Cervix
Chlamydia trachomatis persistence in, 909
human papillomavirus in
in human immunodeficiency virus infection, 1239
types, 1097
squamous intraepithelial lesions, in human immunodeficiency virus infection, vitamin A deficiency and, 1084
T cell localization to, in herpes simplex virus infection type 2, 662
Chagas' disease, treatment, long-term results, 634
Chemokines and chemokine receptors
amphotericin B action on, 1280
in endotoxin exposure, 1264
granulocyte
in endotoxemia, 888
in tuberculosis, 888
in human immunodeficiency virus infection
antiretroviral agent effects on, 751
density on T cells, 1284
genotypes, 1579
inhibitory effects, 68
in lamina propria lymphocytes, 785
mucosal inflammation and, 1625
in pediatric patients, 413
progression in *SDF-1* homozygotes, 311
vs. viral burden, 1247
microglial, thalidomide effects on, 983
myelosuppressing, in ehrlichiosis, 200
in urinary tract infections, 1731, 1738
Chemotaxis, dysfunction, in human immunodeficiency virus infection, 1536
Chickenpox, mortality in, before vaccine licensure, 383
Chlamydia pneumoniae
in atherosclerosis, 1557
infections, pathogenesis, 1678
in major histocompatibility complex down-regulation, 1394
Chlamydia psittaci, shedding, seasonal variation, animal model, 375
Chlamydia trachomatis
cervical persistence, *omp1* genotyping in, 909
culture, inclusion-forming units in, 540
infections, in human immunodeficiency virus infection, interferon-γ deficiency in, 1672
polymorphisms, scarring trachoma risk and, 1545
Chloramphenicol, resistance to, pneumococci, 1417
Chloroquine, for cryptococcosis, 283
Cholera
toxin, T cell effects of, mouse model, 180
vaccination, albendazole effects on, 1199
Vibrio strains causing, epidemic vs. nonepidemic, 1161
Choline-binding protein A, pneumococci, in adhesion, 497
Chorioamnionitis, in human immunodeficiency virus infection, 1652
Ciprofloxacin, resistance to, mycobacteria, 517
Cirrhosis, liver, neutrophil dysfunction in, 526
Citrobacter, Yersinia pestis high-pathogenicity island on, 1268
Clindamycin
for pneumococcal infections, inflammatory response and, 1561
resistance to, pneumococci, 1417
Clostridium perfringens, infections, microvascular dysfunction in, rat model, 799, 808
Cluster analysis, human immunodeficiency virus resistance, 59
Cognitive dysfunction, in human immunodeficiency virus infection, in pediatric patients, 1385
Collectins, in *Candida* defense, 917
Colon
endotoxin in, rat model, 873
inflammation, in human immunodeficiency virus infection, 1625
Colonization
Haemophilus influenzae, prevention with vaccination, 1553
Helicobacter pylori, diarrhea protective effect, in pediatric patients, 1446
Neisseria gonorrhoeae, vaccination effects on, mouse model, 848
pneumococci
antibody development in, 1146

with unusual resistance patterns, 1153
Complement
in pneumococcal adhesion, 497
streptococcal inhibitor of, immune response to, 1425
Congenital infections (*see* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal; Neonatal infections)
Coronary artery disease
enterovirus persistence in, 1222
in Kawasaki disease, immunoglobulin A plasma cell infiltration, 1183
pathogenesis, hepatitis A virus in, 1583
Corticosteroids, for respiratory syncytial virus infections, cotton rat model, 1326
Coxsackievirus, infections, in malnutrition, mouse model, S93
C-reactive protein, in atherosclerosis pathogenesis, 1583
Cryptococcus neoformans
infections
in myeloperoxidase deficiency, mouse model, 1276
treatment, 283
resistance in, mechanisms, 1791
Cryptosporidium parvum, innate immunity to, mouse model, 1001
CTLA-4 antigen, T cell, in malaria, 367
Culture, *Chlamydia trachomatis,* inclusion-forming units in, 540
CysL peptide, human immunodeficiency virus, pathogenic effects, 1643
Cysteine-rich intestinal protein, regulation, zinc in, mouse model, S81
Cystitis, recurrent, risk factors for, in women, 1177
Cytidine deaminase, in meningococcal sepsis, 1784
Cytofluorometric analysis, of T cells, in infections, 474
Cytokeratin 17, expression, in respiratory syncytial virus pathogenesis, 1022
Cytokines *(see also specific cytokines)*
in ascariasis, 1207
dietary polyunsaturated fat effects on, mouse model, S103
in fulminant hepatitis mortality, 1103
in granzyme inhibition, in endotoxemia, 206
in human immunodeficiency virus infection
proinflammatory, 776
with sexually transmitted diseases, 459
imbalance, in zinc deficiency, S62
in influenza, S74
inhibition, by thalidomide, 983
in malaria, vs. severity, 988
monocyte, quinupristin/dalfopristin effects on, 356
in neutrophil migration impairment, mouse model, 214
in placental malaria defense, 960
regulation, antioxidants in, S74
Cytolethal distending toxin, *Helicobacter pullorum,* 620
Cytomegalovirus
antigen detection, in human immunodeficiency virus, with lymphoma in, 376
infections
in kidney transplantation, prediction with molecular assays, 36
in liver transplantation, monitoring for, 1610
prevention, ganciclovir in, 1616
reactivation, during spaceflight, 1761
uterine, glycoprotein B genotypes in, 933
resistance in, mutation causing, 1765
retinitis
resistance in, epidemiology, 1234
thrombospondin inhibition in, 643
treatment, 643, 652
Cytopenia, in ehrlichiosis, pathophysiology, 200

Danish Protease Inhibitor Study, 744
Day care centers, as drug-resistant pneumococcal reservoirs, 1153
Death (*see* Mortality)
Deferoxamine
in pneumococcal meningitis, rat model, 347
T cell subsets and, S115
Delavirdine, for human immunodeficiency virus infection
after indinavir failure, 1375
resistance to, 316
Dendritic cells, in schistosomiasis, 260
Dialysis, hepatitis C virus epidemiology in, The Netherlands, 1291
Diarrhea
astrovirus, epidemiology, Egyptian children, 685
calicivirus, epidemiology, Chile, 1519
Helicobacter pylori colonization protection for, in pediatric patients, 1446
micronutrients and, S134
rotavirus
group C, epidemiology, Sweden, 678
protection against, antibody markers for, 1602
traveler's, enteroaggregative *Escherichia coli* virulence factors in, 1780
vitamin A supplementation in, S122
Didanosine, for human immunodeficiency virus infection, 321, 599
in pediatric patients, 413
Dideoxyinosine, for human immunodeficiency virus infection
granulocyte-macrophage colony-stimulating factor with, 1531
in pediatric patients, 413
resistance to, 316
Diethylcarbamazine, for microfilariasis, 564
Dihydrofolate reductase, *Plasmodium falciparum,* mutations, 624, 993
Dihydropteroate synthase, *Pneumocystis carinii,* mutations, 551, 1192
Dilated cardiomyopathy, enterovirus persistence in, 1222
Diphtheria, epidemiology, at United States–Mexico border, 1503
DNA analysis, for cytomegalovirus, in kidney transplantation, 36
DNA vaccines, hepatitis C virus, mouse model, 18
Docosahexaenoic acid, dietary, immune effects, mouse model, S54, S103
Drug abuse
feline immunodeficiency virus infection progression in, 725
hepatitis C in, 1588
Drug resistance
acyclovir, herpes simplex virus type 1, 290
Cryptococcus neoformans, mechanisms, 1791
cytomegalovirus
epidemiology, 1234
mutation causing, 1765
Enterococcus faecium, vancomycin, host specificity, 816
erythromycin, pneumococci, 490
fluoroquinolones, mycobacteria, 517
hepatitis C virus, interferon-α, 1511
herpes simplex virus type 1, acyclovir, 290
human immunodeficiency virus, 758
in female genital tract, 112
indinavir, 59
mutations in, 330
nonnucleoside reverse-transcriptase inhibitors, 316
saquinavir, 59
statistical analysis, 59

indinavir, human immunodeficiency virus, 59
interferon-α, hepatitis C virus, 1511
isoniazid, *Mycobacterium tuberculosis,* 1788
macrolides, pneumococci, 1417
malaria, sulfadoxine-pyrimethamine, 624
multiple, cytomegalovirus, 1765
mycobacteria, fluoroquinolones, 517
Mycobacterium tuberculosis, isoniazid, 1788
nonnucleoside reverse-transcriptase inhibitors, human immunodeficiency virus, 316
penicillin, pneumococci, 490, 1153
Plasmodium falciparum
pyrimethamine, 993
sulfadoxine-pyrimethamine, 624
pneumococci
Alaska, 490
macrolides, 1417
unusual patterns, 1153
Pneumocystis carinii, sulfa and sulfone, 551, 1192
pyrimethamine, *Plasmodium falciparum,* 993
saquinavir, human immunodeficiency virus, 59
Staphylococcus aureus, methicillin, 359
streptococci, group B, 168
sulfa and sulfone, *Pneumocystis carinii,* 551, 1192
sulfadoxine-pyrimethamine, malaria, 624
trimethoprim-sulfamethoxazole
pneumococci, 490
Pneumocystis carinii, 551, 1192
vancomycin, *Enterococcus faecium,* 816
Duodenum, endotoxin in, rat model, 873

Ear infections, pathogenesis, rat model, 882
EBNA genes, expression, in transplantation, in pediatric patients, 1013
Echinocandin derivative caspofungin, *Cryptococcus neoformans* cell wall glucan synthesis and, 1791
Efavirenz, for human immunodeficiency virus infection, 599
Ehrlichiosis
Lyme disease coinfection with, transmission, 616
pathophysiology, myelosuppressing chemokines in, 200
Eicosapentaenoic acid, dietary, immune effects, mouse model, S54, S103
Elderly persons, influenza in
micronutrient effects on, S74
pathogenesis, mouse model, 391
ELISA (*see* Enzyme-linked immunosorbent assay)
ELISPOT assay, for rotavirus-specific antibody-secreting cells, in intestinal lamina propria, 1039
emm genes, streptococci group A, tissue site preference and, 1109
Emtricitabine, for human immunodeficiency virus infection, 599
Encephalitis, West Nile virus, treatment with ribavirin, 1214
Encephalopathy, progressive multifocal, AIDS-associated, treatment, 1077
Endocarditis, *Staphylococcus aureus,* resistance to platelet microbicidal proteins, 1251
Endothelium, disruption, in meningitis, mouse model, 978
Endotoxemia, chemokine receptors in, on granulocytes, 888
Endotoxin
chemokine production in, urinary measurement, 1731
in cysteine-rich intestinal protein stimulation, mouse model, S81
granulocyte colony-stimulating factor receptor down-modulation, on neutrophils, 343
intestinal, localization, rat model, 873
monocyte-bound, detection in gram-negative sepsis, in pediatric patients, 1549
monocyte immunoparalysis and, 1264
polymyxin B action on, in *Escherichia coli* infections, 191
in soluble granzyme release, 206
Enolase, streptococcal antibodies reacting with, in rheumatic fever pathogenesis, 1712
Enteritis (*see* Gastroenteritis)
Enterobacter, Yersinia pestis high-pathogenicity island on, 1268
Enterobacteriaceae, *Yersinia pestis* high-pathogenicity island on, 1268
Enterococcus faecium, resistance in, vancomycin, host specificity, 816
Enterocytes, endotoxin in, rat model, 873
Enterotoxins, enteroaggregative *Escherichia coli,* 1780
Enteroviruses
mutation, over 7-year period, 298
persistence, in dilated cardiomyopathy, 1222
env gene, human immunodeficiency virus, mutations, 316
Enzyme immunoassays
for human immunodeficiency virus structural studies, 49
for immunoglobulins, in rotavirus infections, 1602
Enzyme-linked immunosorbent assay
for hepatitis A virus, 12
in human immunodeficiency virus infection cytokine studies, 776
for *Leishmaniasis chagasi,* 997
for Lyme disease, 1455
for nutritional assessment, S108
for rotavirus-specific antibody-secreting cells, in intestinal lamina propria, 1039
Epidemiology
astrovirus diarrhea, Egyptian children, 685
Bordetella pertussis infections, Massachusetts adolescents and adults, 1409
calicivirus diarrhea, Chile, 1519
cytomegalovirus resistance, 1234
hepatitis C virus
Chicago drug users, 1588
in dialysis patients, The Netherlands, 1291
Egypt, 698
hepatitis E virus genotypes, 294
hookworm, in children with bacillus Calmette-Guérin scar, 1800
human herpesvirus 6, in multiple sclerosis, 1321
human herpesvirus 8, Brazil, 1574
infectious disease morbidity, at United States–Mexico border, 1503
methicillin-resistant *Staphylococcus aureus,* New York City, 359
microsporidiosis, United Kingdom, 380
Neisseria meningitidis, serogroup B, United States, 1169
Norwalk-like viruses, 691
pertussis, Massachusetts adolescents and adults, 1409
pneumococci
invasive, North America and Europe, 833
with unusual drug resistance, 1153
poliomyelitis, Pakistan, 6
rotavirus infections, group C, Sweden, 678
streptococcal infections, group B, Canada, 168
Streptococcus pneumoniae antibiotic resistance, Alaska, 490
varicella-zoster virus infection mortality, United States, 383
Epithelial cell(s)
death, in zinc deficiency, S85
intestinal, endotoxin in, rat model, 873
oral, *Candida* inhibition by, 1479
Epithelial cell–derived neutrophil-activating protein-78, in urinary tract infections, 1731
Epstein-Barr virus

infections, acute, T cell subsets in, 451
T cells specific to, longitudinal dynamics, in posttransplant lymphoproliferative disorder, 937
in transplant recipients, in pediatric patients, 1013
Errata
Chlamydia, lipid, atherosclerosis interactions (2000; 181[Suppl 3]: S490), 382
Chlamydia pneumoniae antibiotic susceptibility testing (2000; 181[Suppl 3]:S460), 1581
drug resistance in *Streptococcus pneumoniae* (2000; 181:1971), 382
enterotoxigenic *Escherichia coli* (2000; 181:2071), 382
Helicobacter pylori colonization (2000; 182:1446), 1813
Plasmodium falciparum drug resistance (2000; 181:2023), 1011
Plasmodium falciparum–infected erythrocytes (2000; 182:252), 641
Streptococcus pneumoniae antibodies (2000; 182:158), 1011
Streptococcus pneumoniae carriage (2000; 182:1153), 1581
Erythema nodosum leprosum, pathogenesis, tumor necrosis factor–α in, 1463
Erythrocytes, agglutination, in *Plasmodium falciparum* malaria, 252
Erythromycin, resistance to, pneumococci, 490, 1417
Escherichia coli
enteroaggregative
infections, in human immunodeficiency virus infection, 1540
traveler's diarrhea, virulence factors, 1780
heat-labile toxin, T cell effects of, mouse model, 180
infections, polymyxin B mechanism of action in, 191
Yersinia pestis high-pathogenicity island on, 1268
Estrogen
in *Neisseria gonorrhoeae* colonization, mouse model, 848
in simian immunodeficiency virus transmission inhibition, 708
Ethnic factors, in *Chlamydia trachomatis* culture, 540
Exotoxin, *Clostridium perfringens,* microvascular dysfunction and, rat model, 799, 808
Eye infections, scarring, *Chlamydia trachomatis* polymorphisms and, 1545

Fas signaling, in *Helicobacter pylori* infections, mouse model, 856
Fat and fatty acids, dietary, immune effects, mouse model, S54, S103
Fc receptors, in immunoglobulin A response to pneumococci, 1139
Feline immunodeficiency virus infection, progression, multiple morphine exposures and, 725
Filagrastim, for pneumonia, 970
Filariasis, in human immunodeficiency virus infection, 1804
Fish oils, immune effects, mouse model, S54, S103
Flow cytometry
of granulocytes, in chemokine receptor detection, 888
in human immunodeficiency virus infection cytokine studies, 776
in lipopolysaccharide-bound monocyte detection, in gram-negative sepsis, 1549
of streptococcal enolase antibodies, 1712
of T cells
in human immunodeficiency virus infection, 792
in infections, 474
Fluconazole, for histoplasmosis, 545
Fluorescence-activated cell sorter analysis, of T cells, in posttransplant lymphoproliferative disorder, 937
Fluoroquinolones, resistance to, mycobacteria, 517
Folate, in malaria, S37
FP-21399 fusion inhibitor, for human immunodeficiency virus infection, 607
Fulminant hepatitis, mortality in, cytokine levels and, 1103
Fungal infections *(see specific organisms)*

Fusion inhibitors, FP-21399, for human immunodeficiency virus infection, 607

Ganciclovir
for cytomegalovirus retinitis, thrombospondin inhibition and, 643
oral, pharmacokinetics, in pediatric patients, 1616
Gas gangrene, microvascular dysfunction in, rat model, 799, 808
Gastroenteritis
calicivirus, epidemiology, Chile, 1519
Helicobacter pullorum, cytolethal distending toxin, 620
malnutrition in, vicious cycle in, S134
Norwalk-like virus, genetic diversity, 691
Gastrointestinal tract
integrity, vitamin A and, S23
mucosal lymphocytes of, as human immunodeficiency virus targets, 785
pathology, in streptococcal shock, pig model, 133
vitamin A and, S97
GB (hepatitis G) virus
infections, hepatocellular carcinoma risk in, 1300
replication, without causing liver disease, 1756
Gender differences
in *Chlamydia trachomatis* culture, 540
in human immunodeficiency virus load, 603
Genetic factors
human T lymphotropic virus type I infections, 405
in recurrent urinary tract infections, 1177
Genital tract
female, human immunodeficiency virus resistant variants in, 112
human papillomavirus types in, acquisition, 1097
infections (*see also* Herpes simplex virus, type 2)
Chlamydia trachomatis, culture, 540
Glucan synthesis, inhibition, in *Cryptococcus neoformans,* 1791
Glucocorticoids, for respiratory syncytial virus infections, cotton rat model, 1326
Glutathione, in influenza, S74
Glycoprotein B, cytomegalovirus, in uterine infections, 933
Glycoprotein D, herpes simplex virus type 2, in vaccine preparation, mouse and guinea pig models, 1304, 1311
Glycoprotein IIbIIIa, in gas gangrene pathogenesis, 808
Gonococcal outer membrane preparation, in vaccination, mouse model, 848
Gonorrhea (*see Neisseria gonorrhoeae,* infections)
Gram-negative organisms
infections, granzyme release in, 206
sepsis, lipopolysaccharide-bound monocyte detection in, in pediatric patients, 1549
Granulocyte(s), chemokine receptors on, in tuberculosis and endotoxemia, 888
Granulocyte colony-stimulating factor, receptor for, on neutrophils, endotoxin effects on, 343
Granulocyte-macrophage colony-stimulating factor
for human immunodeficiency virus infection, 1531
inhibition, in meningococcal sepsis, 1784
monocyte, quinupristin/dalfopristin effects on, 356
Granzymes, soluble, release, in endotoxemia, 206
Growth failure, in human immunodeficiency virus infection, in pediatric patients, 1385
Growth-related oncogen-α, in urinary tract infections, 1731
Gut-associated lymphoid tissue, alcohol effects on, *Salmonella typhimurium* resistance and, mouse model, 482

HAART (*see* Highly active antiretroviral therapy)

Haemophilus influenzae, vaccination, colonization prevention in, 1553
Hantavirus cardiopulmonary syndrome, humoral immune response in, 43
Heart, enterovirus persistence in, 1222
Helicobacter pullorum, cytolethal distending toxin, 620
Helicobacter pylori
colonization, diarrhea protective effect, in pediatric patients, 1446
genotypes, in Mexico, 1450
growth, in acidic conditions, loci essential for, 1566
infections
duodenal ulcer in, in pediatric patients, 1007
gastric growth alterations in, mouse model, 856
pathogenesis, 1749
Helminthic infections, micronutrients and, S134
Hemagglutinin, filamentous, *Bordetella pertussis,* immunomodulatory effects, 1286
Hematopoiesis, suppression, in ehrlichiosis, 200
β-Hemolysin, streptococci group B
arthritis severity and, mouse model, 824
mechanism of action, mouse model, 150
Hemophilia, human immunodeficiency virus infection in, hepatitis C with, atypical antibody levels in, liver decompensation in, 590
Hepatitis, fulminant, mortality in, cytokine levels and, 1103
Hepatitis A virus
in atherosclerosis pathogenesis, 1583
infections
epidemiology, at United States–Mexico border, 1503
viremia duration in, 12
vaccination, combined with hepatitis B virus, 1005
Hepatitis B virus, vaccination, combined with hepatitis A virus, 1005
Hepatitis C virus
epidemiology
in dialysis patients, The Netherlands, 1291
Egypt, 698
genotypes, 698
treatment response differences in, 28
infections
chronic, alanine aminotransferase levels in, 1595
epidemiology, Chicago drug users, 1588
genotype 1, treatment, interferon, 397
human immunodeficiency virus infection with, atypical antibody levels in, liver decompensation in, 590
human T cell lymphotropic virus type I infection with, 379
resistance, interferon-α, 1511
transmission, perinatal, 1511
vaccination, DNA, mouse model, 18
Hepatitis E virus
genotypes, 294
novel isolates, in Argentina, 294
Hepatitis G virus
infections, hepatocellular carcinoma risk in, 1300
replication, without causing liver disease, 1756
Hepatocellular carcinoma, risk for, in hepatitis G virus infection, 1300
Hepatocytes, hepatitis G virus replication in, without causing disease, 1756
Herpes simplex virus
type 1, in bone marrow transplant recipients, acyclovir-resistant, 290
type 2
infections, human immunodeficiency virus infection with, 459, 1090
T cell localization to cervix in, 662
vaccination, mouse and guinea pig models, 1304
Herpesviruses *(see specific viruses, e.g.,* Human herpesvirus 8)
Heteroduplex tracking assay, for *env* gene variants, in human immunodeficiency virus, 316
Highly active antiretroviral therapy, for human immunodeficiency virus infection
antibody responses in, 945
CD4 T cell count in, 1527
coreceptor tropism in, 751
drug combinations for, 744
early initiation, 88
interruption of, T cell response in, 766
JC virus load and, 1077
Mycobacterium avium immune response in, 1658
in pediatric patients, 751
T cell biphasic decay with, 1636
vaccination with, 579
virus load response to, 1527
in pediatric patients, 1769
Histoplasma capsulatum, meningitis, treatment, 545
HIV infection (*see* Human immunodeficiency virus infection [type 1 or unspecified])
Hookworm, epidemiology, in children with bacillus Calmette-Guérin scar, 1800
Host defense (*see also* Cellular immune response; Humoral immune response; Immune response)
Candida, pulmonary surfactant protein D in, 917
against meningococci, 1557
micronutrients and, S5
Human granulocytic ehrlichiosis
Lyme disease coinfection with, transmission, 616
pathophysiology, myelosuppressing chemokines in, 200
Human herpesvirus 6, tissue distribution, multiple sclerosis and, 1321
Human herpesvirus 8 (Kaposi's sarcoma–associated)
detection, 306
infections
epidemiology, Brazil, 1574
in human immunodeficiency virus infection, 928, 1809
vertical transmission, 1574
Human immunodeficiency virus (type 1 or unspecified)
antibodies to, treatment effects on, 945
in blood, vs. semen, 79
in female genital tract, 112
genotypes, vs. drug resistance, 59
phagocytosis, 338
quasi-species analysis, in interleukin-2 therapy, 1063
replication, 338
PRO 542 effects on, 326
selenium in, S69
in semen, shedding patterns, 79
strains, vaccine development and, 579
subtypes of, structures of, 49
variants, disease progression and, 1579
Human immunodeficiency virus infection (type 1 or unspecified)
acute (*see subheading* primary [acute])
advanced, virus load in, 603
animal models (*see also* Simian immunodeficiency virus infection)
feline immunodeficiency virus, 725
in bacterial vaginosis, 467
candidiasis in
inhibition by oral epithelial cells, 1479

mucosal, 955
cervical squamous intraepithelial lesions in, vitamin A deficiency and, 1084
chemokines in (*see* Chemokines and chemokine receptors, in human immunodeficiency virus infection)
Chlamydia trachomatis infections in, interferon-γ deficiency in, 1672
cross-clade immunity in, vaccine development and, 579
cytokine production in, proinflammatory, 776
cytomegalovirus infections in, retinitis, 1234
Escherichia coli infections in, 1540
filariasis in, 1804
ganciclovir pharmacokinetics in, 1616
hepatitis C with, atypical antibody levels in, liver decompensation in, 590
herpes simplex virus type 2 infections in, interactions between, 1090
human herpesvirus 8 infections in, 928, 1809
human papillomavirus infections in, 1239
JC virus infection in, treatment, 1077
Kaposi's sarcoma in, 1809
leukocyte apoptosis in, 1536
lymphoma in, cytomegalovirus antigen detection in, 376
malaria in, placental, cytokine responses in, malaria with, 960
malnutrition in, S108
mucosal inflammation in, 1625
Mycobacterium avium–intracellulare infections in
Highly active antiretroviral therapy effects on, 1658
prevention, 611
nonprogression
chimpanzee model, 1051
T cell response in, 792
vaccine development and, 579
opportunistic infection prevention in, 611
pathogenesis
chemokines in, 68
T cell cytolysis in, 338
transactivator protein in, 1643
vaccine development and, 579
in pediatric patients (*see* Pediatric patients, human immunodeficiency virus infection in)
placental abnormalities in, 1652
Pneumocystis carinii infections in, prevention, 611, 1192
in pregnancy, malaria with, cytokine responses in, 960
primary (acute)
duration vs. prognosis, 334
T cell biphasic decay in, 1636
T cell subsets in, 451
treatment, 950
progression, 1247, 1579
in chemokine *SDF-1* homozygotes, 311
chimpanzee model, 1051
incubation time and, 334
in pediatric patients, 104, 413, 1385
selenium deficiency and, S69
T cell response in, 792
after treatment, in pediatric patients, 1385
resistance (drug) in, 758
in female genital tract, 112
mutations in, 330
nonnucleoside reverse-transcriptase inhibitors, 316
statistical analysis, 59
subtype E envelope peptides in, 442
vaccine development and, 579
resistance to transmission and progression, 123, 1810, 1811
in Argentinian population, 1523
immune activation in, 1365
treatment and, 420
retinitis in, cytomegalovirus, 1234
selenium deficiency in, disease progression and, S69
sexually transmitted diseases with, viral load in, 459
strains, identification, in criminal transmission, 941
subtype E envelope peptides, for vaccines, 442
survival, in chemokine *SDF-1* homozygotes, 311
susceptibility to, human leukocyte antigen alleles in, 1523
T cells in
with acute sexually transmitted diseases, 459
antiretroviral therapy effects on, 950
biphasic decay, 1636
chemokine receptor density on, 1284
in chemokine *SDF-1* homozygotes, 311
chimpanzee model, 1051
cytolysis, 338
in drug antagonism, 321
in exposure without seroconversion, 1365
functional evaluation, bacteriophage phiX174 immunization in, 435
highly active antiretroviral therapy effects on, 1527
interleukin-2 effects on, 428
interleukin-12 effects on, 1070
proliferative ability loss in, 792
prophylactic antibiotics and, 611
replication-competent virus in, 751
response to human herpesvirus 8 lytic proteins, 928
specificity, 792
subsets, 474
during acute infection, 451
treatment interruption and, 766
transmission
bacterial vaginosis and, 467
criminal, strain identification in, 941
lack of, in discordant partners, 123
perinatal, 1243, 1652
prevention, 104
resistance to (*see subheading* resistance to transmission and progression)
treatment
antagonism in, 321
antibody responses in, 945
antiretroviral agents *(see* Highly active antiretroviral therapy; *specific agents)*
CD4-IgG2, 1774
combination, 744
Danish Protease Inhibitor Study, 744
didanosine (*see* Didanosine)
drug switching in, 733
efavirenz, 599
emtricatabine, 599
failure, 1375
FP-21399 fusion inhibitor, 607
granulocyte-macrophage colony-stimulating factor, 1531
indinavir (*see* Indinavir)
interleukin-2, 428, 1063
interleukin-12, 1070
interruption, T cell response in, 766
lamivudine (*see* Lamivudine)

natural resistance and, 420
nonnucleoside reverse-transcriptase inhibitors, 316
once daily, 599
in pediatric patients, 96, 104
primary (acute), 950
PRO 542, 326
progression after, in pediatric patients, 1385
ritonavir (*see* Ritonavir)
salvage, 1375
saquinavir (*see* Saquinavir)
stavudine, 96, 321
therapeutic immunization in, 579
zidovudine (*see* Zidovudine)
tuberculosis in, thalidomide for, tumor necrosis factor–α production in, 639
vaccination, 49
biological considerations for, 579
clade relevance in, 1350
disease severity spectrum and, 1357
subtype E envelope peptides, 442
virus load in
in advanced disease, 603
antiretroviral therapy effects on, 950
vs. chemokine receptor density, 1284
in drug switching, 733
gender differences in, 603
highly active antiretroviral therapy effects on, 1527, 1769
hormonal effects on, 375
indicators of, 1247
in interleukin-2 therapy, 1063
Human leukocyte antigens
genotypes, malaria vaccine response and, 1486
in human immunodeficiency virus susceptibility, 1523
Human papillomavirus
genital tract, acquisition, 1097
infections, in human immunodeficiency virus infection, 1239
persistence, cytotoxic T cell dysfunction in, 595
Human T cell lymphotropic virus type I
infections
gene predisposing to, in pediatric patients, 405
hepatitis C with, 379
pathogenesis, 1044
subgroups, vs. disease risks, 1343
Humoral immune response (*see also* Antibody[ies]; B cells; Immunoglobulin[s])
to hantavirus, 43
to highly active antiretroviral therapy, for human immunodeficiency virus infection, 945
to influenza virus, in elderly, mouse model, 391
to Norwalk virus vaccine, in transgenic potatoes, 302
to pneumococci, 158, 1139
in infant vaccination, 1260
to rotavirus, 1039
Hypotension, hemolysin-induced, in streptococcal group B infections, mouse model, 150

Ileum, endotoxin in, rat model, 873
Immune complexes, in Lyme disease, pathogen-specific antigen in, 534
Immune response
aging and, S74
to antiretroviral therapy, for human immunodeficiency virus infection, 950
to *Ascaris lumbricoides,* 1207
to *Candida,* 1479
carotenoid effects on, S11
cross-protective, to streptococci group A and group B, mouse model, 133
to *Cryptosporidium parvum,* 1001
to *Escherichia coli* heat-labile toxin, mouse model, 180
to gram-negative infections, 206
to hantavirus, 43
to herpes simplex virus type 2, 662
vaccination, mouse and guinea pig models, 1304, 1311
to highly active antiretroviral therapy, for human immunodeficiency virus infection, 945
to human immunodeficiency virus, 474
in exposure without seroconversion, 1365
in resistant persons, 123, 1810, 1811
in vaccination, 1350
to influenza virus, S74
in elderly, mouse model, 391
vaccination, in pediatric patients, 1218
to *Leishmania* homologue of receptors for activated C-kinase, 570
in liver cirrhosis, 526
to malaria peptide vaccine, vs. HLA genotypes, 1486
micronutrients and (*see* Micronutrients; *specific micronutrients*)
to mycobacteria, 474, 895
to *Mycobacterium tuberculosis,* 234
to *Neisseria gonorrhoeae* vaccination, mouse model, 848
to Norwalk virus vaccine, in transgenic potatoes, 302
to *Plasmodium,* 367
to pneumococci, 158, 1139
antibiotic class and, 1561
in vaccination, 965, 1260
to respiratory syncytial virus
with pertussis toxin sensitization, mouse model, 1029
in vaccination, 1331
to *Salmonella,* 474
to *Schistosoma,* 260
to streptococcal inhibitor of complement, 1425
Immune transfer, adoptive, in cytomegalovirus retinitis, mouse model, 652
Immunization (*see* Vaccination)
Immunoblot assay, strip, for hantavirus, 43
Immunocytochemistry, human immunodeficiency virus infection, 338
Immunodeficiency (*see also* Human immunodeficiency virus infection [type 1 or unspecified]; Transplantation)
cytomegalovirus retinitis in, adoptive immune transfer in, mouse model, 652
enterovirus mutation rate in, over 7-year period, 298
in liver cirrhosis, 526
severe combined, *Cryptosporidium parvum* immune response in, 1001
Immunoglobulin(s)
deficiency, in vitamin A deficiency, S97
detection, in hantavirus cardiopulmonary syndrome, 43
Immunoglobulin A
in plasma cells, infiltration, in Kawasaki disease, 1183
polysaccharide-specific, response to pneumococcal vaccination, 1139
response to poliovirus vaccination, 1
rotavirus, 1039, 1602
Immunoglobulin E, *Plasmodium*-specific, in umbilical cord blood, 558
Immunoglobulin G

anti-capsular, after *Haemophilus influenzae* vaccination, 1553
fusion protein with CD4 molecule, in human immunodeficiency virus infection, 326
rotavirus, 1602
Immunoglobulin M, formation, in hepatitis A, 12
Immunohistochemistry
gastric growth alterations, in *Helicobacter pylori* infections, mouse model, 856
mucosal inflammation, in human immunodeficiency virus infection, 1625
Immunostaining, *Bartonella bacilliformis*, 865
Inclusion-forming units, in *Chlamydia trachomatis* culture, 540
Incontinence, urinary, in pertussis, 174
Indinavir, for human immunodeficiency virus infection
in combinations, 744
failure, 1375
neutrophil apoptosis and, 1536
primary, 950
resistance to, 59, 758
switching from saquinavir, 733
Inflammation, micronutrients and, S5
Inflammatory bowel disease, mucosal inflammation in, 1625
Influenza
cysteine-rich intestinal protein expression in, mouse model, S81
micronutrient effects on, S74
pathogenesis, in elderly persons, mouse model, 391
vaccination, in pediatric patients, 1218
Innate immunity
micronutrients and, S5
vitamin A and, S23
Intercellular adhesion molecule
amphotericin B action on, 1280
in *Chlamydia pneumoniae* infections, 1678
Interferon(s)
in hepatitis C
alanine aminotransferase measurement in, 1595
evolutional studies, 397
in influenza, S74
Interferon-α, resistance to, hepatitis C virus, 1511
Interferon-α2b, in hepatitis C, response to, vs. genotype, 28
Interferon-γ
in ascariasis, 1207
after Chagas' disease treatment, 634
in *Cryptosporidium parvum* innate immunity, mouse model, 1001
deficiency
in *Chlamydia trachomatis* infections, in human immunodeficiency virus infection, 1672
dietary fat and, mouse model, S54
in streptococcal group B infections, in neonates, 974
in zinc deficiency, S62, S81
in human immunodeficiency virus infection
in exposure without seroconversion, 1365
interleukin-12 effects on, 1070
Leishmania homologue of receptors for activated C-kinase and, 570
in mycobacterial inhibition, 895
in placental malaria defense, 960
therapeutic
for *Mycobacterium avium–intracellulare* complex infections, 1664
for visceral leishmaniasis, mouse model, 1497
in tuberculosis, 234
Interferon regulator factor–1, induction by retinoic acid, mouse model, S29
Interleukin(s)
in ascariasis, 1207
deficiency, in zinc deficiency, mouse model, S81
in diethylcarbamazine therapy, for microfilariasis, 564
excess, in zinc deficiency, mouse model, S81
in fulminant hepatitis mortality, 1103
in granzyme inhibition, in endotoxemia, 206
in human immunodeficiency virus infection
in exposure without seroconversion, 1365
proinflammatory, 776
selenium supplementation effects on, S69
with sexually transmitted diseases, 459
in influenza, S74, 391
in malaria, vs. severity, 988
in meningococcal infections, 363
monocyte, quinupristin/dalfopristin effects on, 356
in neutrophil migration impairment, mouse model, 214
in placental malaria defense, 960
soluble receptors, in fulminant hepatitis mortality, 1103
zinc deficiency effects on, S62
Interleukin-1
genotypes, meningococcal disease mortality and, 1557
in tuberculosis defense, mouse model, 902
Interleukin-1β, in bacterial vaginosis, human immunodeficiency virus infection susceptibility and, 467
Interleukin-2, for human immunodeficiency virus infection, 428, 1063
Interleukin-2 receptor-β, induction by retinoic acid, mouse model, S29
Interleukin-4, in immune response, to *Escherichia coli* heat-labile toxin, mouse model, 180
Interleukin-8
amphotericin B action on, 1280
in *Chlamydia pneumoniae* infections, 1678
in ehrlichiosis, 200
microglial, thalidomide effects on, 983
transactivator protein–induced, in human immunodeficiency virus, 1643
tumor necrosis factor p75 soluble receptor Fc conjugate induction of, 1722
in urinary tract infections, 1731
in scarring prevention, mouse model, 1738
Interleukin-10
in candidiasis, mouse model, 266
Chlamydia pneumoniae–generated, in major histocompatibility complex down-regulation, 1394
Leishmania homologue of receptors for activated C-kinase and, 570
polymorphisms, scarring trachoma risk and, 1545
therapeutic, for pneumococcal pneumonia, mouse model, 1255
Interleukin-10:tumor necrosis factor–α ratio, in malaria complication prediction, 1570
Interleukin-12
deficiency
dietary fat and, mouse model, S54
in streptococcal group B infections, in neonates, 974
therapeutic, for human immunodeficiency virus infection, 1070
in visceral leishmaniasis, mouse model, 1497
Interleukin-18, in tuberculosis, 234
Intestine, endotoxin in, rat model, 873
Iron
in malaria, S37
overload, in transfusions, immunologic effects, S115

ISIS 2922 antisense oligonucleotide, for cytomegalovirus retinitis, thrombospondin inhibition and, 643
Isoniazid, resistance to, *Mycobacterium tuberculosis,* 1788
Itraconazole, for histoplasmosis, 545
Ixodes spinipalpis ticks, in Lyme disease–ehrlichiosis cotransmission, 616

JC virus, infections, in human immunodeficiency virus infection, treatment, 1077
Jejunum, endotoxin in, rat model, 873
Joint infections
  Staphylococcus epidermidis, 351
  streptococci group B, mouse model, 824
Junctional adhesion molecules, antibodies to, in meningitis, mouse model, 978

Kaposi's sarcoma, in human immunodeficiency virus infection, 1809
Kaposi's sarcoma–associated herpesvirus (*see* Human herpesvirus 8)
katG gene, mutations, isoniazid resistance in, 1788
Kawasaki disease, immunoglobulin A plasma cell infiltration in, 1183
Kidney
  immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
  infections
    chemokine production in, 1731
    scarring in, mouse model, 1738
  transplantation, cytomegalovirus infections in, prediction with molecular assays, 36
Klebsiella pneumoniae
  respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
  Yersinia pestis high-pathogenicity island on, 1268

Lactulose/mannitol test, for vitamin A, S97
Lamina propria
  chemokine receptors of, in human immunodeficiency virus infection, 785
  endotoxin in, rat model, 873
  rotavirus-specific antibody-secreting cells in, 1039
Lamivudine, for human immunodeficiency virus infection
  genotypic resistance and, 420
  granulocyte-macrophage colony-stimulating factor with, 1531
  in pediatric patients, 96
  primary, 950
Latency-associated nuclear antigen, of Kaposi's sarcoma–associated herpesvirus, 306
Leishmania chagasi, human reservoirs, 997
Leishmania homologue of receptors for activated C-kinase, natural killer cell response to, 570
Leishmaniasis, visceral, treatment, mouse model, 1497
Leprosy, pathogenesis, tumor necrosis factor–α in, 1463
Leukocyte(s)
  apoptosis, in human immunodeficiency virus infection, 1536
  subarachnoid space invasion, in meningitis, mouse model, 978
Linear discrimination analysis, human immunodeficiency virus resistance, 59
Lipopolysaccharide (*see* Endotoxin)
Lipopolysaccharide-binding protein, in diethylcarbamazine therapy, for microfilariasis, 564
Listeria monocytogenes
  immune response to, vs. dietary fat components, mouse model, S54
  meningitis, pathogenesis, mouse model, 978
Liver
  cirrhosis, neutrophil dysfunction in, 526
  hepatocellular carcinoma, hepatitis G risk in, 1300
  inflammation (*see also* Hepatitis)
    in streptococcal shock, pig model, 133
  transplantation
    cytomegalovirus infections in, monitoring for, 1610
    neutrophil evaluation in, 526
LMP genes, expression, in transplantation, in pediatric patients, 1013
Lung
  immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
  infections (*see* Pneumonia; Tuberculosis)
  inflammation, in streptococcal shock, pig model, 133
Lutein, in monocyte function, S11
Lycopene, in monocyte function, S11
Lyme disease
  Alzheimer's disease and, 1006
  human granulocytic ehrlichiosis coinfection with, transmission, 616
  immune complexes in, pathogen-specific antigen in, 534
  serodiagnosis, genetic diversity complications in, 1455
  VlsE lipoprotein antigenic conservation in, mouse model, 1455
Lymphadenopathy, in feline immunodeficiency virus infection, acute morphine exposure effects on, 725
Lymphocyte(s) (*see also* B cells; T cells)
  human herpesvirus 6 in, 1321
  intestinal, chemokine receptors of, in human immunodeficiency virus infection, 785
Lymphocytic choriomeningitis virus, meningitis, mouse model, 978
Lymphoid tissue
  T cell cytolysis in, in human immunodeficiency virus infection, 338
  transfer, in cytomegalovirus retinitis, mouse model, 652
Lymphoma, in human immunodeficiency virus infections, cytomegalovirus antigen detection in, 376
Lymphopenia, in zinc deficiency, mouse model, S16
Lymphoproliferative disorder, posttransplant, Epstein-Barr virus–associated, longitudinal dynamics, 937

Macrolides, resistance to, pneumococci, 1417
Macrophage(s)
  amphotericin B action on, 1280
  apoptosis, *Mycobacterium tuberculosis* in, 240
  cytokine response of, in human immunodeficiency virus infection, 776
  function, micronutrients and, S5
  in human immunodeficiency virus–infected T cell phagocytosis, 338
  in human immunodeficiency virus infection, chemokines and, 68
  lamina propria, endotoxin in, rat model, 873
  nitric oxide production in, by streptococci group B hemolysin, mouse model, 150
  response to pneumococci, antibiotic class and, 1561
Macrophage colony-stimulating factor, for *Mycobacterium avium–intracellulare* complex infections, 1664
Macrophage inflammatory proteins
  amphotericin B action on, 1280
  in ehrlichiosis, 200
  in human immunodeficiency virus infection, 1247, 1625
  microglial, thalidomide effects on, 983

Major histocompatibility complex
down-regulation, *Chlamydia pneumoniae* in, 1394
DQ-DRB haplotype, in simian immunodeficiency virus progression, 716
Malaria
in human immunodeficiency virus infection, in pregnancy, cytokine responses in, 960
nutritional impact on, S37
Plasmodium falciparum
complication prediction in, interleukin-10:tumor necrosis factor–α ratio in, 1570
erythrocyte agglutination in, 252
resistance in, 624
severe, in pediatric patients, 988
treatment, parasite clearance after, 629
vaccination, HLA genotypes and, 1486
T cells in, antigen CTLA-4 measurement in, 367
transmission, perinatal, 558
Malnutrition (*see also specific nutrients, subheading* deficiency)
in enteric infections, vicious cycle in, S134
immunodeficiency in, phenotypic considerations in, S108
malaria morbidity and mortality in, S37
viral infections in, mouse model, S93
Manosylated lipoarabinomannan, in *Mycobacterium tuberculosis*–induced macrophage apoptosis studies, 240
Measles
epidemiology, at United States–Mexico border, 1503
vitamin A supplementation in, S122
Mebendazole, in trichinosis, 371
Melioidosis, granzyme release in, 206
Meningitis
Histoplasma capsulatum, treatment, 545
meningococcal, RANTES in, 363
pathogenesis, endothelial cell dysfunction in, mouse model, 978
pneumococcal
antioxidants for, rat model, 347
prognosis, 840
treatment, rat model, 1437
treatment, thalidomide, 983
Meningococci
infections, mortality in, interleukin-1 genotype associated with, 1557
meningitis, RANTES in, 363
sepsis, cytidine deaminase in, 1784
serogroup B, epidemiology, United States, 1169
Meningoencephalitis
Candida, treatment with amphotericin B lipid formulations, rabbit model, 274
chronic, enteroviral, mutations over 7-year period, 298
Menstrual cycle, human immunodeficiency virus load and, 375
Methicillin, resistance to, *Staphylococcus aureus,* 359
Microfilariasis, treatment, diethylcarbamazine, 564
Microglia, chemokine production by, thalidomide effects on, 983
Micronutrients *(see also specific nutrients)*
research objectives in, S139
workshop on (Bethesda, MD, September 1999), Supplement 1
Microsatellite analysis, *Plasmodium falciparum* dihydrofolate reductase, 993
Microsporidiosis, waterborne, United Kingdom, 380
Migration inhibitory factor–related proteins (calprotectin), recombinant, zinc-reversible antimicrobial activity, 1272
Minerals *(see* Trace elements; *specific minerals)*
Models, for micronutrient studies, S1
Monoclonal antibodies
in lipopolysaccharide-bound monocyte detection, in gram-negative sepsis, 1549
for respiratory syncytial virus infections, cotton rat model, 1326
Monocyte(s)
amphotericin B action on, 1280
cytokine production in, quinupristin/dalfopristin effects on, 356
function, carotenoids in, S11
immunoparalysis, endotoxin in, 1264
lipopolysaccharide bound to, detection in gram-negative sepsis, in pediatric patients, 1549
migration, in human immunodeficiency virus, transactivator protein in, 1643
T cell contact with, in leprosy, 1463
Monocyte chemoattractant protein
amphotericin B action on, 1280
in ehrlichiosis, 200
microglial, thalidomide effects on, 983
Morphine, acute exposures to, feline immunodeficiency virus infection progression in, 725
Mortality
Bartonella bacilliformis infections, in nonendemic populations, 865
candidiasis, in human immunodeficiency virus infection, mouse model, 955
childhood infections, vitamin A supplementation and, S122
fulminant hepatitis, cytokine levels and, 1103
human immunodeficiency virus infection
in pediatric patients, 1385
T cell subsets and, 474
malaria, nutritional impact on, S37
meningococcal disease, interleukin-1 genotype associated with, 1557
mycobacteria infections, T cell subsets and, 474
nutrient deficiencies, S1
pneumococcal infections
ceftriaxone effects on, mouse model, 1255
North America and Europe, 833, 840
Salmonella infections, T cell subsets and, 474
varicella-zoster virus infections, before vaccine licensure, 383
Mosquito-borne diseases, West Nile virus encephalitis, treatment, 1214
Mucin, formation, in mucoid otitis media pathogenesis, rat model, 882
Mucoid otitis media, pathogenesis, rat model, 882
Mucosa, candidiasis, in human immunodeficiency virus infection, mouse model, 955
Mucosal immunity, to human immunodeficiency virus, 579
Multiple sclerosis, human herpesvirus 6 distribution and, 1321
Mumps, epidemiology, at United States–Mexico border, 1503
Mutations (*see also* Polymorphisms)
dihydrofolate reductase, *Plasmodium falciparum,* 624, 993
dihydropteroate synthase
Plasmodium falciparum, 624
Pneumocystis carinii, 551, 1192
drug resistance due to (*see* Drug resistance)
env gene, human immunodeficiency virus, 316
fluoroquinolone resistance in, 517
Helicobacter pylori, for acidic growth conditions, 1566
human immunodeficiency virus, 330
katG gene, isoniazid resistance in, 1788
streptococcal inhibitor of complement, 1425
Mycobacteria
recombinant reporter, for immunity evaluation, 895
resistance in, fluoroquinolones, 517
Mycobacterium avium–intracellulare complex, infections

in human immunodeficiency virus infection
highly active antiretroviral therapy effects on, 1658
prevention, 611
immunopathology, 1664
T cells in, 474
Mycobacterium leprae, infections, pathogenesis, tumor necrosis factor–α in, 1463
Mycobacterium tuberculosis (*see also* Tuberculosis)
in macrophage apoptosis, mechanism of, 240
Myelopathy, human T cell lymphotropic virus type I–associated, 1044, 1343
Myeloperoxidase deficiency, pulmonary infections in, mouse model, 1276
Myelopoietic cells, zinc deficiency effects on, mouse model, S16
Myocardial ischemia, enterovirus persistence in, 1222
Myocarditis, coxsackievirus, in malnutrition, mouse model, S93
Myositis, in trichinosis, treatment, 371

NAD glycohydrolase, in streptococcal toxic shock syndrome, 1117
Nasal immunization, respiratory syncytial virus, mouse model, 671
National Institutes of Health, research on micronutrient-infection interactions, S139
Natural (innate) immunity
micronutrients and, S5
vitamin A and, S23
Necator americanus, epidemiology, bacillus Calmette-Guérin vaccination scars and, 1800
Neisseria gonorrhoeae
colonization, vaginal, vaccination effects on, mouse model, 848
infections, human immunodeficiency virus infection with, virus load in, 459
vaccination, nasal, mouse model, 848
Neisseria meningitidis (*see* Meningococci)
Nelfinavir, for human immunodeficiency virus infection
genotypic resistance and, 420
after indinavir failure, 1375
resistance to, 758
Neonatal infections
cytomegalovirus, glycoprotein B genotypes, 933
hepatitis C virus, 1511
human immunodeficiency virus, 1243
Plasmodium, transmission, 558
streptococcal group B
hemolysin mechanism of action in, mouse model, 150
pathogenesis, 974
Neutrophil(s)
apoptosis, in human immunodeficiency virus infection, 1536
dysfunction, in liver cirrhosis, 526
function, micronutrients and, S5
granulocyte colony-stimulating factor receptor, endotoxin effects on, 343
Helicobacter pylori activation, 1749
migration inhibition of, in sepsis, mouse model, 214
sensitization to bacteria, polymyxin B in, 191
Neutrophil-activating protein-78, epithelial cell–derived, in urinary tract infections, 1731
nga gene, streptococci group A, 1117
Nitric oxide
in neutrophil migration inhibition, in sepsis, mouse model, 206
production of, streptococci group B hemolysin, mouse model, 150
Nitric oxide synthase, accumulation, in antibiotic therapy, for pneumococcal infections, 1561
NK cells
dysfunction, in zinc deficiency, S62
function, micronutrients and, S5
in human immunodeficiency virus infections, 474
in mycobacterial infections, 474
response, to *Leishmania* homologue of receptors for activated C-kinase, 570
in *Salmonella* infections, 474
Nonspecific (innate) immunity
micronutrients and, S5
vitamin A and, S23
Norwalk and Norwalk-like viruses
genetic diversity, 691
vaccination, in transgenic potatoes, 302
Nuclear factor–κB
in *Chlamydia pneumoniae* infections, 1678
inhibitors, in pneumococcal meningitis, rat model, 1437
Nuclisens test, for cytomegalovirus, in kidney transplantation, 36
Nutrition
micronutrients in (*see* Micronutrients; *specific vitamins and minerals*)
status, assessment, S108

Omega-3 fatty acids, immune effects, mouse model, S54, S103
Onchocerciasis, diagnosis, 1796
Oral cavity, epithelium, *Candida* inhibition by, 1479
Oroya fever, natural history, in nonendemic populations, 865
Otitis media
mucoid, pathogenesis, rat model, 882
pneumococci, antibody development in, 1146
Outbreaks, microsporidiosis, United Kingdom, 380
Oxacillin, for pneumococcal infections, inflammatory response and, 1561

$p21^{Waf1/Cip1}$ cell cycle regulator, activation, in zinc deficiency, S85
Palivizumab, for respiratory syncytial virus infections, cotton rat model, 1326
P-AMP test, for cytomegalovirus, in kidney transplantation, 36
Pancreas, immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
Paraparesis, tropical spastic
pathogenesis, 1044
risks for, 1343
Pathogenicity islands, *Yersinia pestis,* on Enterobacteriaceae, 1268
Pediatric patients (*see also* Neonatal infections)
ascariasis in, albendazole treatment, cholera vaccine response and, 1199
astrovirus diarrhea in, epidemiology, Egypt, 685
bone marrow transplantation in, pneumococcal vaccination in, 965
calicivirus diarrhea in, Chile, 1519
ganciclovir pharmacokinetics in, in pediatric patients, 1616
gram-negative sepsis in, lipopolysaccharide-bound monocyte detection in, 1549
Helicobacter pylori in
colonization, diarrhea protective effect, 1446
infections, duodenal ulcer in, 1007
human immunodeficiency virus infection in
antibodies in, 1243
ganciclovir pharmacokinetics in, 1616
perinatal transmission, 1243
progression, 413
treatment, 96, 104, 413
CD4-IgG2, 1774
early initiation, 88
highly active antiretroviral therapy, 88, 751, 1769

progression after, 1385
virus load, CD4-IgG2 effects on, 1774
human T lymphotropic virus type I infections in, gene predisposing to, 405
influenza vaccination in, 1218
malaria in, severe, 988
meningococcal infections in, RANTES in, 363
Plasmodium falciparum malaria in, erythrocyte agglutination in, 252
transplantation in, Epstein-Barr virus persistence in, 1013
varicella-zoster virus infections in, mortality in, 383
vitamin A supplementation in, morbidity and mortality and, S122
Pelvic inflammatory disease, human immunodeficiency virus infection with, virus load in, 459
Penicillin(s), resistance to, pneumococci, 490, 1153
Penicillin V, in streptococci group A tonsillopharyngitis, 509
Peptic ulcer disease, *Helicobacter pylori*
pathogenesis, 1749
in pediatric patients, 1007
Peritonitis, neutrophil migration impairment in, mouse model, 214
Pertactin, polymorphism in, 1402
Pertussis
epidemiology, Massachusetts adolescents and adults, 1409
morbidity, in adolescents and adults, 174
toxins in
polymorphism in, 1402
sensitization with, respiratory syncytial virus infection pathogenesis in, 1029
vaccination, 1286, 1575
respiratory syncytial virus infection pathogenesis after, mouse model, 1029
Phagocytosis
deficiency, in liver cirrhosis, 526
human immunodeficiency virus–infected T cells, 338
in tuberculosis, pulmonary surfactant in, 1473
Pharyngitis, streptococci group A
treatment, 509
tropical vs. nontropical, 1109
Phospholipase C, in gangrene, rat model, 799, 808
Placenta, abnormalities, in human immunodeficiency virus infection, 1652
Plasma cells, immunoglobulin A, infiltration, in Kawasaki disease, 1183
Plasmid-encoded toxin, enteroaggregative *Escherichia coli,* 1780
Plasmodium
infections, T cells in, antigen CTLA-4 measurement in, 367
in umbilical cord blood, 558
Plasmodium falciparum, infections
complication prediction in, interleukin-10:tumor necrosis factor–α ratio in, 1570
erythrocyte agglutination in, 252
nutritional impact on, S37
resistance in, 624, 993
severe, in pediatric patients, 988
treatment, parasite clearance after, 629
vaccination, HLA genotypes and, 1486
Platelet(s), glycoprotein IIbIIIa, in gas gangrene pathogenesis, 808
Platelet microbicidal proteins, resistance to, in *Staphylococcus aureus* endocarditis, 1251
Pneumocandins, *Cryptococcus neoformans* cell wall glucan synthesis and, 1791
Pneumococci *(Streptococcus pneumoniae)*
adhesion, choline-binding protein A in, 497
antibodies to, in colonization, 1146
bacteremia, treatment with filagrastim, 970
colonization, with unusual resistance patterns, 1153
infections, invasive, prognosis, North America and Europe, 833, 840
invasive
epidemiology, invasive, North America and Europe, 833, 840
resistance in, Alaska, 490
macrophage inflammatory response to, antibiotic class and, 1561
meningitis, antioxidants for, rat model, 347
pneumonia, treatment
ceftriaxone, mouse model, 1255
filagrastim, 970
resistance in
Alaska, 490
macrolides, 1417
unusual patterns, 1153
respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
serotypes, invasive, North America and Europe, 833, 840
surface adhesin A, antibodies to, 1146
surface protein A
antibodies to, 1146
in vaccine preparation, 1694
vaccination
antibody studies, 158
in bone marrow transplantation, in children, 965
immunoglobulin A response in, 1139
mouse model, 1694
salivary antibody response, in infants, 1260
Pneumocystis carinii
dihydropteroate synthase mutations in, 551, 1192
infections, in human immunodeficiency virus infection, prevention, 611, 1192
resistance in, sulfa and sulfone, 551, 1192
Pneumolysin, antibodies to, in pneumococcal colonization, 1146
Pneumonia
Bordetella pertussis, 174
pneumococcal
antibody measurement in, 158
prognosis, 840
treatment, ceftriaxone, mouse model, 1255
respiratory syncytial virus, treatment, cotton rat model, 1326
treatment, filagrastim, 970
vitamin A supplementation in, S122
Poliomyelitis
epidemiology, Pakistan, 6
vaccination
failure in Pakistan, 6
intestinal antibody responses in, 1
viral mutation in, in chronic infection, over 7-year period, 298
Polymerase chain reaction
for *Borrelia,* 1006
for cytomegalovirus, 1616, 1761
in adoptive immune transfer, mouse model, 652
in kidney transplantation, 36
in liver transplantation, 1610
for enteroaggregative *Escherichia coli,* 1780
for feline immunodeficiency virus infection, 725
for *Helicobacter pylori,* 1450
for hepatitis C virus, 1511
for hepatitis G virus, 1756
for human leukocyte antigen alleles, in human immunodeficiency virus infection, 1523
for human papillomavirus types, 1097

nested reverse-transcriptase, for hepatitis A virus, 12
for *Plasmodium,* 558
for *Plasmodium falciparum* dihydrofolate reductase, 993
for *Pneumocystis carinii* mutations, 551
reverse transcriptase
for enterovirus, 1222
for hepatitis C virus, 698, 1291
for Norwalk-like virus, 691
for rotavirus, 678
for *Vibrio cholerae* strains, 1161
for *Yersinia pestis* high-pathogenicity islands, 1268
Polymorphisms (*see also* Mutations)
Bordetella pertussis toxins, 1402
Chlamydia trachomatis, scarring trachoma risk and, 1545
Polymyxin B, mechanism of action, in *Escherichia coli* infections, 191
Polyriboinosinic acid, vitamin A synergism with, tetanus toxoid response in, mouse model, S29
PorA region, *Neisseria meningitidis* serogroup B, epidemiology, United States, 1169
Potatoes, transgenic, Norwalk virus vaccine delivery in, 302
Pregnancy
cytomegalovirus infections in, glycoprotein B genotypes, 933
human immunodeficiency virus infection in (*see also* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal)
malaria with, cytokine responses in, 960
streptococcal group B infections in, epidemiology, Canada, 168
PRO 542 entry inhibitor, for human immunodeficiency virus infection, 326
Progesterone, in simian immunodeficiency virus transmission, 708
Progressive multifocal leukoencephalopathy, AIDS-associated, treatment, 1077
Prostaglandin E_2, in *Chlamydia pneumoniae* infections, 1678
Prosthetic joint infections, *Staphylococcus epidermidis,* 351
Protease inhibitors *(see specific drugs)*
Protein energy malnutrition
immunodeficiency in, phenotypic considerations in, S108
malaria morbidity and mortality in, S37
Pseudomonas aeruginosa, respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Public health structure, at United States–Mexico border, disease morbidity and, 1503
Pulmonary surfactant
in phagocytosis, in tuberculosis, 1473
protein D, in *Candida* defense, 917
Purified protein skin test, tuberculosis, improved delayed-type hypersensitivity reaction in, mouse model, 224
Pyelonephritis
chemokine production in, 1731
scarring in, mouse model, 1738
Pyridoxine (vitamin B6), in malaria, S37
Pyrimethamine, resistance to, *Plasmodium falciparum,* 993

Quinacrine, for cryptococcosis, 283
Quinine, for malaria, parasite clearance and, 629
Quinupristin/dalfopristin, in monocyte cytokine production, 356
Quorum-sensing phenotype, *Staphylococcus aureus,* in biofilms, 1688

Rabies, epidemiology, at United States–Mexico border, 1503
Racial factors, in *Chlamydia trachomatis* culture, 540
RANTES
in ehrlichiosis, 200
in human immunodeficiency virus infection, 68, 1247, 1625
in meningococcal disease, 363
microglial, thalidomide effects on, 983
Recursive partitioning analysis, human immunodeficiency virus resistance, 59
Regulated upon activation, normal T cell expressed and secreted (*see* RANTES)
Reporter gene bioassay, for *Yersinia pestis* high-pathogenicity islands, 1268
Respiratory infections (*see also* Pneumonia; Tuberculosis)
Chlamydia pneumoniae, pathogenesis, 1678
hantavirus, humoral immune response in, 43
Mycobacterium avium–intracellulare complex infections, T cell dysfunction in, 1664
in myeloperoxidase deficiency, mouse model, 1276
vitamin A supplementation in, S122
Respiratory syncytial virus
infections
mouse model, 671
pathogenesis, cytokeratin 17 in, 1022
with pertussis toxin sensitization, mouse model, 1029
treatment, cotton rat model, 1326
SH gene, conservation, 1228
vaccination
live intranasal, 1331
mouse model, 671
Respiratory tract, immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
Restriction fragment length polymorphism analysis, for hepatitis C virus, 698
Retinitis, cytomegalovirus
resistance in, epidemiology, 1234
treatment, 643, 652
Retinoic acid, in vitamin A deficiency, tetanus toxoid response in, mouse model, S29
Retinol (*see* Vitamin A)
Retinol-binding protein, gut integrity and, S97
Rheumatic fever, pathogenesis, 1712
Ribavirin, for West Nile virus encephalitis, 1214
Riboflavin (vitamin B2), in malaria, S37
Ritonavir, for human immunodeficiency virus infection
in combinations, 744, 758
after indinavir failure, 1375
neutrophil apoptosis and, 1536
in pediatric patients, 96
River blindness (onchocerciasis), diagnosis, 1796
Rotavirus
antibody-secreting cells specific to, in intestinal lamina propria, 1039
group C, genetic diversity, 678
infections
group C, epidemiology, Sweden, 678
protection against, antibody markers for, 1602
Rubella, epidemiology, at United States–Mexico border, 1503

Saliva
human herpesvirus 6 in, 1321
pneumococcal antibodies in, after vaccination, 1260
Salmonella, infections
epidemiology, at United States–Mexico border, 1503
T cells in, 474
Salmonella typhimurium, infections, alcohol consumption and, mouse model, 482
Sand flies, *Leishmania chagasi* transmission to, from humans, 997
Saquinavir, for human immunodeficiency virus infection

in combinations, 744
granulocyte-macrophage colony-stimulating factor with, 1531
hard-capsule vs. soft-capsule, 733
resistance to, 59, 316, 758
Sargramostim, for human immunodeficiency virus infection, 1531
Scarring, in pyelonephritis, mouse model, 1738
Schistosomiasis, chronic, T cell responses in, 260
Segregation analysis, human T lymphotropic virus type I infections, 405
Selenium, deficiency
coxsackievirus infections in, mouse model, S93
in human immunodeficiency virus, disease progression and, S69
Semen, human immunodeficiency virus in, shedding patterns, 79
Sepsis
gram-negative, lipopolysaccharide-bound monocyte detection in, in pediatric patients, 1549
meningococci, cytidine deaminase in, 1784
monocyte immunoparalysis in, 1264
neonatal, in streptococcal group B infections, mouse model, 150
neutrophil migration impairment in, mouse model, 214
treatment, tumor necrosis factor p75 soluble receptor Fc conjugate in, 1722
Septic arthritis, streptococci group B, severity vs. β-hemolysin expression, mouse model, 824
Septicemia, pneumococcal, ceftriaxone effects on, mouse model, 1255
Septic shock, meningococcal, RANTES in, 363
Sexual activity, recurrent urinary tract infections and, 1177
Sexually transmitted diseases *(see also specific diseases)*
human immunodeficiency virus infection with, virus load in, 459
SH gene, respiratory syncytial virus, conservation, 1228
Shigella
enterotoxins, 1780
infections, epidemiology, at United States–Mexico border, 1503
Shock
septic, meningococcal, RANTES in, 363
streptococcal, serogroup A, pathophysiology, pig model, 133
in toxic shock syndrome, streptococci group A, virulence factors, 1117
Sickle cell disease, zinc deficiency in, immune status in, S62
Signal transducer and activator of transcription–1, induction by retinoic acid, mouse model, S29
Simian immunodeficiency virus, in human immunodeficiency virus vaccine preparation, 579
Simian immunodeficiency virus infection
progression, rapid, 716
transmission, estrogen protective effect in, 708
Sin Nombre virus, humoral immune response to, 43
Skin lesions, streptococci group A
pathogenesis, 1702
tropical vs. nontropical, 1109
Skin tests
for nutritional assessment, S108
for tuberculosis, improved delayed-type hypersensitivity reaction in, mouse model, 224
Skin window technique, for neutrophil evaluation, in liver cirrhosis, 526
Small intestine, rotavirus-specific antibody-secreting cells in, 1039
Smoking, pertussis morbidity in, 174
SN50 peptide, for cytomegalovirus retinitis, thrombospondin inhibition and, 643
Soft-tissue infections
streptococci group A, pathogenesis, 1702
streptococci group B, epidemiology, Canada, 168
Spaceflight, cytomegalovirus reactivation during, 1761
Spinal cord disorders, human T cell lymphotropic virus type I–associated, 1044, 1343
Squamous intraepithelial lesions, cervical, in human immunodeficiency virus infection, vitamin A deficiency and, 1084
Staphylococcus aureus
in biofilms, *agr* quorum-sensing phenotype, 1688
endocarditis, resistance to platelet microbicidal proteins, 1251
resistance in, methicillin, 359
respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Staphylococcus epidermidis, strains, invasive vs. normal flora, 351
Statistical analysis, human immunodeficiency virus resistance, 59
Stavudine, for human immunodeficiency virus infection
in pediatric patients, 96
zidovudine antagonism with, 321
Stomach, growth alterations in, in *Helicobacter pylori* infections, mouse model, 856
Streptococcal inhibitor of complement, immune response to, 1425
Streptococci
group A *(Streptococcus pyogenes)*
cross-protection between group B, mouse model, 133
infections
shock in, pathophysiology, pig model, 133
treatment, 509
tropical vs. nontropical, 1109
mouse-passaged highly encapsulated variant, characterization, 1702
in rheumatic fever pathogenesis, 1712
streptococcal inhibitor of complement derived from, 1425
toxic shock syndrome, virulence factors, 1117
group B
cross-protection between group A, mouse model, 133
β-hemolysin
arthritis severity and, mouse model, 824
mechanism of action, mouse model, 150
infections, epidemiology, Canada, 168
pathogenesis, in neonates, 974
resistance to, 168
vaccination, with tetanus toxoid, 1129
Streptococcus pneumoniae (*see* Pneumococci [*Streptococcus pneumoniae*])
Streptococcus pyogenes (*see* Streptococci, group A [*Streptococcus pyogenes*])
Subarachnoid space, leukocyte invasion, in meningitis, mouse model, 978
Sulfadoxine-pyrimethamine, resistance to, malaria, 624
Surfactant, pulmonary
in phagocytosis, in tuberculosis, 1473
protein D, in *Candida* defense, 917
Syncytia, cytopathic, formation in respiratory syncytial virus infection, 1022

tax gene, human T cell lymphotropic virus type I, variants, 1343
T cells
antigen-specific, localization to cervix, in herpes simplex virus infections type 2, 662
CD4, proliferative ability, in human immunodeficiency virus infection, 792
CD8
response, to human herpesvirus 8 lytic proteins, 928
subsets, in acute viral infections, 451

cytotoxic
Epstein-Barr virus–specific, in posttransplant lymphoproliferative disorder, 937
in human immunodeficiency virus resistance, 723
human papillomavirus persistence and, 595
localization to cervix, in herpes simplex virus infections type 2, 662
dietary polyunsaturated fat effects on, mouse model, S103
dysfunction
in influenza, mouse model, 391
in *Mycobacterium avium–intracellulare* complex infections, 1664
Escherichia coli heat-labile toxin effects on, mouse model, 180
helper, imbalance, in zinc deficiency, S62
in human immunodeficiency virus infection (*see* Human immunodeficiency virus infection [type 1 or unspecified], T cells in)
human T cell lymphotropic virus type I–infected, blood-brain barrier penetration by, 1044
in malaria, antigen CTLA-4 measurement in, 367
monocyte contact with, in leprosy, 1463
in schistosomiasis, 260
subsets
in mycobacterial infections, 474
in *Salmonella* infections, 474
in transfusion-related iron overload, S115
transfer, in cytomegalovirus retinitis, mouse model, 652
zinc deficiency effects on, mouse model, S16
Tetanus vaccination
with streptococci group B, 1129
in vitamin A deficiency, mouse model, S29
Thalassemia, transfusion-related iron overload in, immunologic effects, S115
Thalidomide
for human immunodeficiency virus–tuberculosis coinfection, tumor necrosis factor–α production in, 639
immunomodulatory properties, 983
Thiabendazole, in trichinosis, 371
Thiamine (vitamin B1), in malaria, S37
Throat infections, streptococci group A, tropical vs. nontropical, 1109
Thrombospondins, inhibition, in cytomegalovirus retinitis, 643
Thymidine kinase
herpes simplex virus type 1, genetic characterization, acyclovir resistance and, 290
zinc deficiency effects on, S62
Thymulin, deficiency, in zinc deficiency, S62
Thymus, atrophy, in zinc deficiency, mouse model, S16
Tick bites (*see* Ehrlichiosis; Lyme disease)
Tonsillopharyngitis, streptococci group A, treatment, 509
Toxic shock syndrome, streptococci group A, virulence factors, 1117
Toxins (*see also* Endotoxin)
Bordetella pertussis, polymorphism in, 1402
cholera
strains producing, 1161
T cell effects of, mouse model, 180
Clostridium perfringens, microvascular dysfunction and, rat model, 799, 808
enteroaggregative *Escherichia coli,* 1780
Escherichia coli heat-labile, mouse model, 180
Helicobacter pullorum, 620
pertussis, sensitization with, respiratory syncytial virus infection pathogenesis in, 1029
Staphylococcus aureus, in biofilm formation, 1688
Vibrio cholerae
strains producing, 1161
T cell effects of, mouse model, 180
Trace elements *(see also specific elements)*
deficiency, immunodeficiency in, S108
macrophage function and, S5
neutrophil function and, S5
NK cell function and, S5
Trachea, immunoglobulin A plasma cell infiltration, in Kawasaki disease, 1183
Trachoma, scarring, *Chlamydia trachomatis* polymorphisms and, 1545
Transactivator protein, human immunodeficiency virus, pathogenic effects, 1643
Transforming growth factor–β1, in malaria, vs. severity, 988
Transfusions, iron overload in, immunologic effects, S115
Transgenic potatoes, Norwalk virus vaccine delivery in, 302
Transplantation
bone marrow
herpes simplex virus type 1 resistance in, 290
lymphoproliferative disorder after, Epstein-Barr virus–associated, longitudinal dynamics, 937
pneumococcal vaccination in, in children, 965
human herpesvirus 8 infections in, 1809
Kaposi's sarcoma in, 1809
kidney, cytomegalovirus infections in, prediction with molecular assays, 36
liver
cytomegalovirus infections in, monitoring for, 1610
neutrophil evaluation in, 526
in pediatric patients, Epstein-Barr virus persistence in, 1013
Traveler's diarrhea, enteroaggregative *Escherichia coli* virulence factors in, 1780
Triamcinolone, for respiratory syncytial virus infections, cotton rat model, 1326
Trichinosis, myositis in, treatment, 371
Trichosporon asahii, respiratory infections, in myeloperoxidase deficiency, mouse model, 1276
Trimethoprim-sulfamethoxazole, resistance to
pneumococci, 490
Pneumocystis carinii, 551, 1192
Tropical spastic paraparesis
pathogenesis, 1044
risks for, 1343
Trylizad-mesylate, in pneumococcal meningitis, rat model, 347
Trypanosomiasis, American (Chagas' disease), treatment, long-term results, 634
Tuberculosis *(see also Mycobacterium tuberculosis)*
chemokine receptors in, on granulocytes, 888
human immunodeficiency virus infection with, thalidomide for, tumor necrosis factor–α production in, 639
immunity to, evaluation with recombinant reporter mycobacteria, 895
interleukin-1 signaling in, mouse model, 902
interleukin-18 production in, 234
phagocytosis in, pulmonary surfactant in, 1473
resistance in
fluoroquinolones, 517
isoniazid, 1788
skin tests for, improved delayed-type hypersensitivity reaction in, mouse model, 224
T cells in, 474
Tumor necrosis factor–α

accumulation, in antibiotic therapy, for pneumococcal infections, 1561
in bacterial vaginosis, human immunodeficiency virus infection susceptibility and, 467
deficiency, in zinc deficiency, mouse model, S81
in diethylcarbamazine therapy, for microfilariasis, 564
in fulminant hepatitis mortality, 1103
genotypes, meningococcal disease mortality and, 1557
in human immunodeficiency virus infection
in exposure without seroconversion, 1365
with sexually transmitted diseases, 459
in influenza, S74
interleukin-10 ratio with, in malaria complication prediction, 1570
in leprosy pathogenesis, 1463
in malaria with human immunodeficiency virus infection, 960
in meningococcal infections, 363
monocyte, quinupristin/dalfopristin effects on, 356
in mucoid otitis media pathogenesis, rat model, 882
in mycobacterial inhibition, 895
in neutrophil migration impairment, mouse model, 214
polymorphisms, scarring trachoma risk and, 1545
regulation, selenium in, S69
soluble receptors, in diethylcarbamazine therapy, for microfilariasis, 564
streptococcal shock, group A, pig model, 133
in thalidomide therapy, for human immunodeficiency virus–tuberculosis coinfection, 639
Tumor necrosis factor p75 soluble receptor Fc conjugate in, for sepsis, 1722

Umbilical cord blood
cytokines in, in streptococcal group B infections, 974
Plasmodium detection in, 558
Urethritis, *Chlamydia trachomatis,* culture in, 540
Urinary incontinence, in pertussis, 174
Urinary tract infections
chemokine production in, 1731
recurrent, risk factors for, in women, 1177
scarring in, mouse model, 1738
Urine, human herpesvirus 6 in, 1321
Uterus, cytomegalovirus infection, glycoprotein B genotypes in, 933

vacA gene, *Helicobacter pylori,* genotypes, in Mexico, 1450
Vaccination
bacillus Calmette-Guérin, hookworm epidemiology and, 1800
Bordetella pertussis, 1286
evaluation, 1575
respiratory syncytial virus infection pathogenesis after, mouse model, 1029
cholera, albendazole effects on, 1199
Haemophilus influenzae, colonization prevention in, 1553
hepatitis B/hepatitis A combination, 1005
hepatitis C virus, DNA, mouse model, 18
herpes simplex virus type 2, mouse and guinea pig models, 1304, 1311
human immunodeficiency virus, 49
biological considerations for, 579
clade relevance in, 1350
disease severity spectrum and, 1357
subtype E envelope peptides in, 442
influenza, in pediatric patients, 1218
malaria, HLA genotypes and, 1486
Neisseria gonorrhoeae, nasal, mouse model, 848
Norwalk virus, in transgenic potatoes, 302
pertussis, 1286, 1575
pneumococci
antibody studies for, 158
in bone marrow transplantation, in children, 965
immunoglobulin A response in, 1139
mouse model, 1694
salivary antibody response, in infants, 1260
poliomyelitis
failure, in Pakistan, 6
intestinal antibody responses in, 1
respiratory syncytial virus
live intranasal, 1331
mouse model, 671
streptococci group B, with tetanus toxoid, 1129
tetanus
with streptococci group B, 1129
in vitamin A deficiency, mouse model, S29
varicella-zoster virus, mortality before, 383
Vibrio cholerae, albendazole effects on, 1199
Vagina, *Neisseria gonorrhoeae* colonization, vaccination effects on, mouse model, 848
Vaginosis, bacterial, human immunodeficiency virus infection susceptibility in, 467
Vancomycin, resistance to, *Enterococcus faecium,* host specificity, 816
Varicella-zoster virus, infections, mortality in, before vaccine licensure, 383
Vascular dysfunction, in gas gangrene, rat model, 799, 808
Vascular endothelial growth factor, transactivator protein–induced, in human immunodeficiency virus, 1643
Verruga peruana, natural history, in nonendemic populations, 865
Vibrio cholerae
O139, strains, 1161
toxin, T cell effects of, mouse model, 180
vaccination, albendazole effects on, 1199
Virulence factors
Bordetella pertussis, polymorphisms in, 1402
Candida, in human immunodeficiency virus infection, mouse model, 955
Escherichia coli, enteroaggregative, 1780
Helicobacter pullorum, 620
streptococci group A, in toxic shock syndrome, 1117
Vibrio cholerae, 1161
Virus infections, meningitis, pathogenesis, mouse model, 978
Visceral leishmaniasis
transmission, 997
treatment, mouse model, 1497
Vitamin(s)
deficiency, immunodeficiency in, phenotypic considerations in, S108
macrophage function and, S5
neutrophil function and, S5
NK cell function and, S5
Vitamin A
deficiency
in human immunodeficiency virus infection, cervical squamous intraepithelial lesions and, 1084
intestinal integrity impairment in, S97
innate immunity and, S23
in malaria, S37
polyriboinosinic acid synergism with, tetanus toxoid response in, mouse model, S29
supplementation, morbidity and mortality and, S122

Vitamin B1 (thiamine), in malaria, S37
Vitamin B2 (riboflavin), in malaria, S37
Vitamin B6 (pyridoxine), in malaria, S37
Vitamin C
  in influenza, S74
  in malaria, S37
Vitamin E
  in influenza, S74
  in malaria, S37

Waterborne diseases, microsporidiosis, United Kingdom, 380
Western blot test
  for *Bartonella bacilliformis,* 865
  for Kaposi's sarcoma–associated herpesvirus, 306
West Nile virus, encephalitis, treatment with ribavirin, 1214
Wheezing, in respiratory syncytial virus infections, mouse model, 671
Whooping cough (*see* Pertussis)

Yersiniabactin, gene for, 1268
Yersinia pestis, high-pathogenicity island, on Enterobacteriaceae, 1268

Zalcitabine, for human immunodeficiency virus infection, granulocyte-macrophage colony-stimulating factor with, 1531
ZEBRA gene, expression, in transplantation, in pediatric patients, 1013
Zidovudine, for human immunodeficiency virus infection
  genotypic resistance and, 420
  granulocyte-macrophage colony-stimulating factor with, 1531
  in pediatric patients, 96, 104, 413
  primary, 950
  resistance to, 316
  stavudine antagonism with, 321
Zinc
  deficiency
    cysteine-rich intestinal protein and, mouse model, S81
    epithelial cell death in, S85
    helper T cell imbalance in, S62
    lymphocyte dysfunction in, mouse model, S16
  in malaria, S37